Remodeling and Repair of Orthopedic Tissue: Role of Mechanical Loading and BiologicsPart II: Cartilage and Bone

Article Type
Changed
Thu, 09/19/2019 - 13:58
Display Headline
Remodeling and Repair of Orthopedic Tissue: Role of Mechanical Loading and Biologics
Part II: Cartilage and Bone

Article PDF
Author and Disclosure Information

Chang Soo Lee, MD, Spencer E. Szczesny, MS, and Louis J. Soslowsky, PhD

Dr. Lee is Visiting Scholar, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, and Assistant Professor, Department of Orthopaedic Surgery, Inje University Ilsanpaik Hospital, Goyang-si, Gyeonggi-do, Korea.

Mr. Szczesny is Graduate Student, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, and Bioengineering Department, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania.

Dr. Soslowsky is Fairhill Professor of Orthopedic Surgery, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, and Professor of Bioengineering, Bioengineering Department, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania.

Issue
The American Journal of Orthopedics - 40(3)
Publications
Topics
Page Number
122-128
Legacy Keywords
remodeling; repair; mechanical loading; biologics; Remodeling and Repair of Orthopedic Tissue; Role of Mechanical Loading and Biologics; Szczesny; Lee; Soslowsky; American Journal of Orthopedics; bone; cartilage, ajo
Author and Disclosure Information

Chang Soo Lee, MD, Spencer E. Szczesny, MS, and Louis J. Soslowsky, PhD

Dr. Lee is Visiting Scholar, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, and Assistant Professor, Department of Orthopaedic Surgery, Inje University Ilsanpaik Hospital, Goyang-si, Gyeonggi-do, Korea.

Mr. Szczesny is Graduate Student, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, and Bioengineering Department, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania.

Dr. Soslowsky is Fairhill Professor of Orthopedic Surgery, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, and Professor of Bioengineering, Bioengineering Department, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania.

Author and Disclosure Information

Chang Soo Lee, MD, Spencer E. Szczesny, MS, and Louis J. Soslowsky, PhD

Dr. Lee is Visiting Scholar, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, and Assistant Professor, Department of Orthopaedic Surgery, Inje University Ilsanpaik Hospital, Goyang-si, Gyeonggi-do, Korea.

Mr. Szczesny is Graduate Student, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, and Bioengineering Department, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania.

Dr. Soslowsky is Fairhill Professor of Orthopedic Surgery, McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, and Professor of Bioengineering, Bioengineering Department, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania.

Article PDF
Article PDF

Issue
The American Journal of Orthopedics - 40(3)
Issue
The American Journal of Orthopedics - 40(3)
Page Number
122-128
Page Number
122-128
Publications
Publications
Topics
Article Type
Display Headline
Remodeling and Repair of Orthopedic Tissue: Role of Mechanical Loading and Biologics
Part II: Cartilage and Bone
Display Headline
Remodeling and Repair of Orthopedic Tissue: Role of Mechanical Loading and Biologics
Part II: Cartilage and Bone
Legacy Keywords
remodeling; repair; mechanical loading; biologics; Remodeling and Repair of Orthopedic Tissue; Role of Mechanical Loading and Biologics; Szczesny; Lee; Soslowsky; American Journal of Orthopedics; bone; cartilage, ajo
Legacy Keywords
remodeling; repair; mechanical loading; biologics; Remodeling and Repair of Orthopedic Tissue; Role of Mechanical Loading and Biologics; Szczesny; Lee; Soslowsky; American Journal of Orthopedics; bone; cartilage, ajo
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Tissue Engineering Strategies for Rotator Cuff Repair

Article Type
Changed
Thu, 09/19/2019 - 13:58
Display Headline
Tissue Engineering Strategies for Rotator Cuff Repair

Article PDF
Author and Disclosure Information

Joseph P. Iannotti, MD, PhD, and Kathleen A. Derwin, PhD

Dr. Iannotti is Maynar Madden Professor and Chairman, Orthopaedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, Ohio.

Dr. Derwin is Assistant Staff Scientist, Cleveland Clinic, Assistant Professor, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Issue
The American Journal of Orthopedics - 40(3)
Publications
Topics
Page Number
114-115
Legacy Keywords
Use of Extracellular Matrix Patches for Rotator Cuff Tear Augmentation; Iannotti; Derwin; rotator cuff; repair; tear; augmentation; The American Journal of Orthopedics; ajo, matrix patches; extracellular, graft, platelet rich plasma, prp
Sections
Author and Disclosure Information

Joseph P. Iannotti, MD, PhD, and Kathleen A. Derwin, PhD

Dr. Iannotti is Maynar Madden Professor and Chairman, Orthopaedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, Ohio.

Dr. Derwin is Assistant Staff Scientist, Cleveland Clinic, Assistant Professor, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Author and Disclosure Information

Joseph P. Iannotti, MD, PhD, and Kathleen A. Derwin, PhD

Dr. Iannotti is Maynar Madden Professor and Chairman, Orthopaedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, Ohio.

Dr. Derwin is Assistant Staff Scientist, Cleveland Clinic, Assistant Professor, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Article PDF
Article PDF

Issue
The American Journal of Orthopedics - 40(3)
Issue
The American Journal of Orthopedics - 40(3)
Page Number
114-115
Page Number
114-115
Publications
Publications
Topics
Article Type
Display Headline
Tissue Engineering Strategies for Rotator Cuff Repair
Display Headline
Tissue Engineering Strategies for Rotator Cuff Repair
Legacy Keywords
Use of Extracellular Matrix Patches for Rotator Cuff Tear Augmentation; Iannotti; Derwin; rotator cuff; repair; tear; augmentation; The American Journal of Orthopedics; ajo, matrix patches; extracellular, graft, platelet rich plasma, prp
Legacy Keywords
Use of Extracellular Matrix Patches for Rotator Cuff Tear Augmentation; Iannotti; Derwin; rotator cuff; repair; tear; augmentation; The American Journal of Orthopedics; ajo, matrix patches; extracellular, graft, platelet rich plasma, prp
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

A Novel Technique for Preparing an Allograft Fibula for Use as a Transsacral Graft as Treatment for High-grade Spondylolisthesis

Article Type
Changed
Thu, 09/19/2019 - 13:58
Display Headline
A Novel Technique for Preparing an Allograft Fibula for Use as a Transsacral Graft as Treatment for High-grade Spondylolisthesis

Article PDF
Author and Disclosure Information

Matthew D. Milewski, MD, Peter G. Whang, MD, and Jonathan N. Grauer, MD

Dr. Milewski is Chief Resident, Dr. Whang is Assistant Professor, and Dr. Grauer is Associate Professor, Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut.

Issue
The American Journal of Orthopedics - 40(3)
Publications
Topics
Page Number
130-133
Legacy Keywords
bone transplantation; spondylolisthesis; fusion; fibula; decompression; lumbar vertebra; allograft, graft, transsacral, anterior cruciate ligament coring reamer, A Novel Technique for Preparing an Allograft Fibula for Use as a Transsacral Graft as Treatment for High-grade Spondylolisthesis; Milewski; Whang; Grauer; The American Journal of Orthopedics, ajo
Sections
Author and Disclosure Information

Matthew D. Milewski, MD, Peter G. Whang, MD, and Jonathan N. Grauer, MD

Dr. Milewski is Chief Resident, Dr. Whang is Assistant Professor, and Dr. Grauer is Associate Professor, Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut.

Author and Disclosure Information

Matthew D. Milewski, MD, Peter G. Whang, MD, and Jonathan N. Grauer, MD

Dr. Milewski is Chief Resident, Dr. Whang is Assistant Professor, and Dr. Grauer is Associate Professor, Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut.

Article PDF
Article PDF

Issue
The American Journal of Orthopedics - 40(3)
Issue
The American Journal of Orthopedics - 40(3)
Page Number
130-133
Page Number
130-133
Publications
Publications
Topics
Article Type
Display Headline
A Novel Technique for Preparing an Allograft Fibula for Use as a Transsacral Graft as Treatment for High-grade Spondylolisthesis
Display Headline
A Novel Technique for Preparing an Allograft Fibula for Use as a Transsacral Graft as Treatment for High-grade Spondylolisthesis
Legacy Keywords
bone transplantation; spondylolisthesis; fusion; fibula; decompression; lumbar vertebra; allograft, graft, transsacral, anterior cruciate ligament coring reamer, A Novel Technique for Preparing an Allograft Fibula for Use as a Transsacral Graft as Treatment for High-grade Spondylolisthesis; Milewski; Whang; Grauer; The American Journal of Orthopedics, ajo
Legacy Keywords
bone transplantation; spondylolisthesis; fusion; fibula; decompression; lumbar vertebra; allograft, graft, transsacral, anterior cruciate ligament coring reamer, A Novel Technique for Preparing an Allograft Fibula for Use as a Transsacral Graft as Treatment for High-grade Spondylolisthesis; Milewski; Whang; Grauer; The American Journal of Orthopedics, ajo
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Dermatologic Manifestations of Musicians: A Case Report and Review of Skin Conditions in Musicians

Article Type
Changed
Tue, 05/07/2019 - 15:00
Display Headline
Dermatologic Manifestations of Musicians: A Case Report and Review of Skin Conditions in Musicians
Article PDF
Issue
Cutis - 87(3)
Publications
Topics
Page Number
117-121
Sections
Article PDF
Article PDF
Issue
Cutis - 87(3)
Issue
Cutis - 87(3)
Page Number
117-121
Page Number
117-121
Publications
Publications
Topics
Article Type
Display Headline
Dermatologic Manifestations of Musicians: A Case Report and Review of Skin Conditions in Musicians
Display Headline
Dermatologic Manifestations of Musicians: A Case Report and Review of Skin Conditions in Musicians
Sections
Disallow All Ads
Alternative CME
Article PDF Media

What's Eating You? Triatome Reduviids

Article Type
Changed
Thu, 01/10/2019 - 12:22
Display Headline
What's Eating You? Triatome Reduviids
Article PDF
Issue
Cutis - 87(3)
Publications
Page Number
114-115
Sections
Article PDF
Article PDF
Issue
Cutis - 87(3)
Issue
Cutis - 87(3)
Page Number
114-115
Page Number
114-115
Publications
Publications
Article Type
Display Headline
What's Eating You? Triatome Reduviids
Display Headline
What's Eating You? Triatome Reduviids
Sections
Disallow All Ads
Alternative CME
Article PDF Media

The mysterious foreign accent

Article Type
Changed
Tue, 12/11/2018 - 15:30
Display Headline
The mysterious foreign accent

CASE: Disruptive and withdrawn

Police bring Ms. D, age 33, to our psychiatric facility because of violent behavior at her group home. When confronted for allegedly stealing, she became upset, fought with a housemate, and spat. Six months before coming to our facility she was admitted to a private hospital for psychotic disorder, not otherwise specified (NOS) where she was mute, refused all food and medications, lay in her room, and covered her face with a sheet when someone tried to talk to her.

Ms. D denies having depressive symptoms, sleep disturbance, racing thoughts, thoughts of hurting herself or others, or auditory or visual hallucinations. She complains of poor appetite. Ms. D denies a history of mental illness and says she is not taking any medication. She is upset about being hospitalized and says she will not cooperate with treatment. We cannot obtain her complete psychiatric history but available records indicate that she has 1 previous psychiatric hospitalization for psychotic disorder NOS, and has received trials of haloperidol, lorazepam, diphenhydramine, escitalopram, ziprasidone, and benztropine. Her records do not indicate the dosages of these medications or how she responded to pharmacotherapy.

During her mental status exam, Ms. D is well dressed, covers her hair with a scarf, has no unusual body movements, and responds to questions appropriately. She describes her mood as “okay” but appears upset and anxious about being in the hospital. She exhibits no overt psychotic symptoms and does not appear to be responding to auditory hallucinations or having delusional thoughts. Her cognitive function is intact and her intelligence is judged to be average with impaired insight and judgment. However, she speaks with a distinct accent that sounds Jamaican; otherwise, her speech is articulate with normal rate and tone. When we ask about her accent, Ms. D, who is African American, does not disclose her ethnicity and seems to be unaware of her accent. We did not question the authenticity of her accent until after we obtained collateral information from her family.

The authors’ observations

Based on the available information, we make a provisional diagnosis of psychotic disorder NOS and Ms. D is admitted involuntarily because of concerns about her safety. She is reluctant to accept any treatment and receives an involuntary probate commitment for 90 days. At admission, Ms. D is evasive, guarded, secretive, and at times hostile. Her physical examination reveals no signs or symptoms of focal neurologic deficits. Laboratory testing, including urine toxicology, is unremarkable. She refuses an MRI. Later testing reveals a critical ammonia level of 143 μg/dL, warranting an axis III diagnosis of asymptomatic hyperammonemia.

HISTORY: Paranoia and delusions

Ms. D says she was born and raised in a southern state. She reports that she was born to an Egyptian mother who died during childbirth; her father, who is white, was an ambassador stationed abroad. Ms. D attended school until the 11thgrade and was married at age 19 to a Secret Service agent. She says she has a son who was kidnapped by her husband’s enemies, rescued by paying ransom, and currently lives with his grandfather. Ms. D is paranoid and fears that her life is in danger. She also believes that she has gluten sensitivity that could discolor and damage her hair, which is why she always keeps a scarf on her head for protection.

Through an Internet search, we find articles about Ms. D’s son’s kidnapping. The 7-year-old had been missing for weeks when police found him with his mother in safe condition in another state, after Ms. D called her mother to ask for money and a place to stay. The child was taken from Ms. D’s custody because of concerns for his safety. We also find Ms. D’s mother. Although Ms. D insists her mother is deceased, after some persuasion, she signs a release allowing us to talk to her.

Ms. D’s mother reports that her daughter’s psychiatric problems began when she was pregnant. At the time Ms. D did not have a foreign accent. She had started to “talk funny” when her psychiatric symptoms emerged after she married and became pregnant.

Foreign accent syndrome

A foreign accent can be acquired by normal phenomena, such as being immersed in a foreign language, or a pathological process,1 which can include psychiatric (functional) or neurologic illness (organic causes). Foreign accent syndrome (FAS) is a rare speech disorder characterized by the appearance of a new accent, different from the speaker’s native language, that is perceived as foreign by the listener and in most cases also by the speaker.2 Usually an FAS patient has had no exposure to the accent, although in some cases an old accent has re-emerged.3,4

 

 

FAS can result from lesions in brain areas involved in speech production, including precentral gyrus, premotor mid-frontal gyrus, left subcortical prerolandic gyrus, postrolandic gyri, and left parietal area.4 Most FAS cases are secondary to a structural lesion in the brain caused by stroke, traumatic brain injury, cerebral hemorrhage, or multiple sclerosis.2 There are a few cases in the literature of acquired foreign accent with psychogenic etiology in patients with schizophrenia and bipolar disorder with psychotic features.5

TREATMENT: Combination therapy

Based on Ms. D’s unstable mood, irritability, delusional beliefs, and paranoid ideas, we start divalproex, 500 mg/d titrated to 1, 750 mg/d, and risperidone, 3 mg in the morning and 4 mg at bedtime.

The unit psychologist evaluates Ms. D and provides individual psychotherapy, which is mainly supportive and psychoeducational. Ms. D gradually becomes cooperative and friendly. She is not willing to talk about her accent or its origin; however, as her psychiatric symptoms improve, her accent gradually diminishes. The accent never completely resolves, but reduces until it is barely noticeable.

The authors’ observations

Ms. D’s foreign accent was more prominent when she displayed positive psychotic symptoms, such as delusions and disorganized thinking, and gradually disappeared as her psychotic symptoms improved. Ms. D’s case was peculiar because her accent was 1 of the first symptoms before her psychosis fully manifested.

How are FAS and psychosis linked?

Language dysfunction in schizophrenia is common and characterized by derailment and disorganization. Severity of language dysfunction in schizophrenia is directly proportional to overall disease severity.6,7 Various hypotheses have suggested the origin of FAS. In patients with FAS secondary to a neurologic disorder, a lesion usually is found in the dominant brain hemisphere, but the cause is not clear in patients with psychosis who have normal MRI findings. One hypothesis by Reeves et al links development of FAS to the functional disconnection between the left dorsolateral prefrontal cortex (DLPFC) and the superior temporal gyrus (STG) during active psychosis.5 In normal speech production, electric impulses originate in the DLPFC and are transmitted to STG in Wernicke’s area. From there, information goes to Broca’s area, which activates the primary motor cortex to pronounce words. In healthy individuals, word generation activates the DLPFC and causes deactivation of the bilateral STG.8 In schizophrenia, the left STG fails to deactivate in the presence of activation of the left DLPFC.9 Interestingly, STG dysfunction is seen only during active phase of psychosis. Its absence in asymptomatic patients with schizophrenia and bipolar disorder10,11 suggest that a foreign accent-like syndrome may be linked to the functional disconnection between the left DLPFC and left STG dysfunction in patients with active psychosis.5

Performing functional neuroimaging, including positron-emission tomography, functional MRI, and single-photon emission computed tomography, of patients with FAS could shed more light on the possible link between FAS and psychosis. In a case report of a patient with bipolar disorder who developed FAS, MRI initially showed no structural lesion but a later functional imaging scan revealed a cerebral infarct in the left insular and anterior temporal cortex.2

One of the limitations in Ms. D’s case is the lack of neuroimaging studies. For the first few weeks of her hospitalization, it was difficult to communicate with Ms. D. She did not acknowledge her illness and would not cooperate with treatment. She was withdrawn and seemed to experience hysterical mutism, which she perceived as caused by extreme food allergies. Later, as her symptoms continued to improve with pharmacologic and psychotherapeutic interventions, neuroimaging was no longer clinically necessary.

OUTCOME: Accent disappears

As Ms. D improves, psychotherapy evolves to gently and carefully challenging her delusions and providing insight-oriented interventions and trauma therapy. As her delusions gradually start to loosen, Ms. D reveals she had been physically and emotionally abused by her husband.

At discharge after 90 days in the hospital, Ms. D’s symptoms are well managed and she no longer shows signs of a thought disorder. Her thinking is clear, rational, and logical. She demonstrates incredible insight and appreciation that she needs to stay in treatment and continue to take divalproex and risperidone. Her delusions appear to be completely resolved and she is focused on reuniting with her son. Many of her previous delusions appear to be related to trauma and partly dissociative.

Ms. D contacts the psychologist several months later to report she is doing well in the community, staying in treatment, and working on legal means to reunite with her son. No trace of any foreign accent is detectable in her voice.

 

 

Related Resources

  • Miller N, Lowit A, O’Sullivan H. What makes acquired foreign accent syndrome foreign? Journal of Neurolinguistics. 2006; 19: 385-409.
  • Tsuruga K, Kobayashi T, Hirai N, et al. Foreign accent syndrome in a case of dissociative (conversion) disorder. Seishin Shinkeigaku Zasshi. 2008; 110(2): 79-87.

Drug Brand Names

  • Benztropine • Cogentin
  • Diphenhydramine • Benadryl
  • Divalproex • Depakote
  • Escitalopram • Lexapro
  • Haloperidol • Haldol
  • Lorazepam • Ativan
  • Risperidone • Risperdal
  • Ziprasidone • Geodon

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

References

1. Miller N, Lowit A, O’Sullivan H. What makes acquired foreign accent syndrome foreign? J Neurolinguistics. 2006;19(5):385-409.

2. Poulin S, Macoir J, Paquet N, et al. Psychogenic or neurogenic origin of agrammatism and foreign accent syndrome in a bipolar patient: a case report. Ann Gen Psychiatry. 2007;6:1.-

3. Takayama Y, Sugishita M, Kido T, et al. A case of foreign accent syndrome without aphasia caused by a lesion of the left precentral gyrus. Neurology. 1993;43:1361-1363.

4. Roth EJ, Fink K, Cherney LR, et al. Reversion to a previously learned foreign accent after stroke. Arch Phys Med Rehabil. 1997;78:550-552.

5. Reeves RR, Burke RS, Parker JD. Characteristics of psychotic patients with foreign accent syndrome. J Neuropsychiatry Clin Neurosci. 2007;19:70-76.

6. Ceccherini-Nelli A, Crow TJ. Disintegration of the components of language as the path to a revision of Bleuler’s and Schneider’s concepts of schizophrenia: linguistic disturbances compared with first-rank symptoms in acute psychosis. Br J Psychiatry. 2003;182:233-240.

7. Harrow M, O’Connell EM, Herbener ES, et al. Disordered verbalizations in schizophrenia: a speech disturbance or thought disorder? Compr Psychiatry. 2003;44:353-359.

8. Friston KJ, Frith CD, Liddle PF, et al. Investigating a network of word generation with positron emission tomography. Proc R Soc Lond B Biol Sci. 1991;244:101-106.

9. Frith CD, Friston K, Herold S, et al. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry. 1995;167:343-349.

10. Spence SA, Liddle PF, Stefan MD, et al. Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Focal dysfunction and distributed disconnectivity reappraised. Br J Psychiatry. 2011;176:52-60.

11. Dye SM, Spence SA, Bench CJ, et al. No evidence for left superior temporal dysfunction in asymptomatic schizophrenia and bipolar disorder. PET study of verbal fluency. Br J Psychiatry. 1999;175:367-374.

Article PDF
Author and Disclosure Information

Panchajanya Paul, MD
Dr. Paul is a Second-Year Resident, Department of Psychiatry, The University of Toledo, Toledo, OH.
Barry Beckman, PsyD
Dr. Beckman is a Psychologist, Northwest Ohio Psychiatrist Hospital, Toledo.
David Bellian, MD
Dr. Bellian is a Psychiatric, Northwest Ohio Psychiatric Hospital, Toledo, and Clinical Assistant Professor of Psychiatry, The University of Toledo.
Thomas Osinowo, MD
Dr. Osinowo is a Psychiatrist, Northwest Ohio Psychiatric Hospital, Toledo, and Clinical Assistant Professor of Psychiatry, The University of Toledo.

Issue
Current Psychiatry - 10(03)
Publications
Topics
Page Number
57-63
Legacy Keywords
foreign accent syndrome; Paul: Beckman; Bellian; Osinowo
Sections
Author and Disclosure Information

Panchajanya Paul, MD
Dr. Paul is a Second-Year Resident, Department of Psychiatry, The University of Toledo, Toledo, OH.
Barry Beckman, PsyD
Dr. Beckman is a Psychologist, Northwest Ohio Psychiatrist Hospital, Toledo.
David Bellian, MD
Dr. Bellian is a Psychiatric, Northwest Ohio Psychiatric Hospital, Toledo, and Clinical Assistant Professor of Psychiatry, The University of Toledo.
Thomas Osinowo, MD
Dr. Osinowo is a Psychiatrist, Northwest Ohio Psychiatric Hospital, Toledo, and Clinical Assistant Professor of Psychiatry, The University of Toledo.

Author and Disclosure Information

Panchajanya Paul, MD
Dr. Paul is a Second-Year Resident, Department of Psychiatry, The University of Toledo, Toledo, OH.
Barry Beckman, PsyD
Dr. Beckman is a Psychologist, Northwest Ohio Psychiatrist Hospital, Toledo.
David Bellian, MD
Dr. Bellian is a Psychiatric, Northwest Ohio Psychiatric Hospital, Toledo, and Clinical Assistant Professor of Psychiatry, The University of Toledo.
Thomas Osinowo, MD
Dr. Osinowo is a Psychiatrist, Northwest Ohio Psychiatric Hospital, Toledo, and Clinical Assistant Professor of Psychiatry, The University of Toledo.

Article PDF
Article PDF

CASE: Disruptive and withdrawn

Police bring Ms. D, age 33, to our psychiatric facility because of violent behavior at her group home. When confronted for allegedly stealing, she became upset, fought with a housemate, and spat. Six months before coming to our facility she was admitted to a private hospital for psychotic disorder, not otherwise specified (NOS) where she was mute, refused all food and medications, lay in her room, and covered her face with a sheet when someone tried to talk to her.

Ms. D denies having depressive symptoms, sleep disturbance, racing thoughts, thoughts of hurting herself or others, or auditory or visual hallucinations. She complains of poor appetite. Ms. D denies a history of mental illness and says she is not taking any medication. She is upset about being hospitalized and says she will not cooperate with treatment. We cannot obtain her complete psychiatric history but available records indicate that she has 1 previous psychiatric hospitalization for psychotic disorder NOS, and has received trials of haloperidol, lorazepam, diphenhydramine, escitalopram, ziprasidone, and benztropine. Her records do not indicate the dosages of these medications or how she responded to pharmacotherapy.

During her mental status exam, Ms. D is well dressed, covers her hair with a scarf, has no unusual body movements, and responds to questions appropriately. She describes her mood as “okay” but appears upset and anxious about being in the hospital. She exhibits no overt psychotic symptoms and does not appear to be responding to auditory hallucinations or having delusional thoughts. Her cognitive function is intact and her intelligence is judged to be average with impaired insight and judgment. However, she speaks with a distinct accent that sounds Jamaican; otherwise, her speech is articulate with normal rate and tone. When we ask about her accent, Ms. D, who is African American, does not disclose her ethnicity and seems to be unaware of her accent. We did not question the authenticity of her accent until after we obtained collateral information from her family.

The authors’ observations

Based on the available information, we make a provisional diagnosis of psychotic disorder NOS and Ms. D is admitted involuntarily because of concerns about her safety. She is reluctant to accept any treatment and receives an involuntary probate commitment for 90 days. At admission, Ms. D is evasive, guarded, secretive, and at times hostile. Her physical examination reveals no signs or symptoms of focal neurologic deficits. Laboratory testing, including urine toxicology, is unremarkable. She refuses an MRI. Later testing reveals a critical ammonia level of 143 μg/dL, warranting an axis III diagnosis of asymptomatic hyperammonemia.

HISTORY: Paranoia and delusions

Ms. D says she was born and raised in a southern state. She reports that she was born to an Egyptian mother who died during childbirth; her father, who is white, was an ambassador stationed abroad. Ms. D attended school until the 11thgrade and was married at age 19 to a Secret Service agent. She says she has a son who was kidnapped by her husband’s enemies, rescued by paying ransom, and currently lives with his grandfather. Ms. D is paranoid and fears that her life is in danger. She also believes that she has gluten sensitivity that could discolor and damage her hair, which is why she always keeps a scarf on her head for protection.

Through an Internet search, we find articles about Ms. D’s son’s kidnapping. The 7-year-old had been missing for weeks when police found him with his mother in safe condition in another state, after Ms. D called her mother to ask for money and a place to stay. The child was taken from Ms. D’s custody because of concerns for his safety. We also find Ms. D’s mother. Although Ms. D insists her mother is deceased, after some persuasion, she signs a release allowing us to talk to her.

Ms. D’s mother reports that her daughter’s psychiatric problems began when she was pregnant. At the time Ms. D did not have a foreign accent. She had started to “talk funny” when her psychiatric symptoms emerged after she married and became pregnant.

Foreign accent syndrome

A foreign accent can be acquired by normal phenomena, such as being immersed in a foreign language, or a pathological process,1 which can include psychiatric (functional) or neurologic illness (organic causes). Foreign accent syndrome (FAS) is a rare speech disorder characterized by the appearance of a new accent, different from the speaker’s native language, that is perceived as foreign by the listener and in most cases also by the speaker.2 Usually an FAS patient has had no exposure to the accent, although in some cases an old accent has re-emerged.3,4

 

 

FAS can result from lesions in brain areas involved in speech production, including precentral gyrus, premotor mid-frontal gyrus, left subcortical prerolandic gyrus, postrolandic gyri, and left parietal area.4 Most FAS cases are secondary to a structural lesion in the brain caused by stroke, traumatic brain injury, cerebral hemorrhage, or multiple sclerosis.2 There are a few cases in the literature of acquired foreign accent with psychogenic etiology in patients with schizophrenia and bipolar disorder with psychotic features.5

TREATMENT: Combination therapy

Based on Ms. D’s unstable mood, irritability, delusional beliefs, and paranoid ideas, we start divalproex, 500 mg/d titrated to 1, 750 mg/d, and risperidone, 3 mg in the morning and 4 mg at bedtime.

The unit psychologist evaluates Ms. D and provides individual psychotherapy, which is mainly supportive and psychoeducational. Ms. D gradually becomes cooperative and friendly. She is not willing to talk about her accent or its origin; however, as her psychiatric symptoms improve, her accent gradually diminishes. The accent never completely resolves, but reduces until it is barely noticeable.

The authors’ observations

Ms. D’s foreign accent was more prominent when she displayed positive psychotic symptoms, such as delusions and disorganized thinking, and gradually disappeared as her psychotic symptoms improved. Ms. D’s case was peculiar because her accent was 1 of the first symptoms before her psychosis fully manifested.

How are FAS and psychosis linked?

Language dysfunction in schizophrenia is common and characterized by derailment and disorganization. Severity of language dysfunction in schizophrenia is directly proportional to overall disease severity.6,7 Various hypotheses have suggested the origin of FAS. In patients with FAS secondary to a neurologic disorder, a lesion usually is found in the dominant brain hemisphere, but the cause is not clear in patients with psychosis who have normal MRI findings. One hypothesis by Reeves et al links development of FAS to the functional disconnection between the left dorsolateral prefrontal cortex (DLPFC) and the superior temporal gyrus (STG) during active psychosis.5 In normal speech production, electric impulses originate in the DLPFC and are transmitted to STG in Wernicke’s area. From there, information goes to Broca’s area, which activates the primary motor cortex to pronounce words. In healthy individuals, word generation activates the DLPFC and causes deactivation of the bilateral STG.8 In schizophrenia, the left STG fails to deactivate in the presence of activation of the left DLPFC.9 Interestingly, STG dysfunction is seen only during active phase of psychosis. Its absence in asymptomatic patients with schizophrenia and bipolar disorder10,11 suggest that a foreign accent-like syndrome may be linked to the functional disconnection between the left DLPFC and left STG dysfunction in patients with active psychosis.5

Performing functional neuroimaging, including positron-emission tomography, functional MRI, and single-photon emission computed tomography, of patients with FAS could shed more light on the possible link between FAS and psychosis. In a case report of a patient with bipolar disorder who developed FAS, MRI initially showed no structural lesion but a later functional imaging scan revealed a cerebral infarct in the left insular and anterior temporal cortex.2

One of the limitations in Ms. D’s case is the lack of neuroimaging studies. For the first few weeks of her hospitalization, it was difficult to communicate with Ms. D. She did not acknowledge her illness and would not cooperate with treatment. She was withdrawn and seemed to experience hysterical mutism, which she perceived as caused by extreme food allergies. Later, as her symptoms continued to improve with pharmacologic and psychotherapeutic interventions, neuroimaging was no longer clinically necessary.

OUTCOME: Accent disappears

As Ms. D improves, psychotherapy evolves to gently and carefully challenging her delusions and providing insight-oriented interventions and trauma therapy. As her delusions gradually start to loosen, Ms. D reveals she had been physically and emotionally abused by her husband.

At discharge after 90 days in the hospital, Ms. D’s symptoms are well managed and she no longer shows signs of a thought disorder. Her thinking is clear, rational, and logical. She demonstrates incredible insight and appreciation that she needs to stay in treatment and continue to take divalproex and risperidone. Her delusions appear to be completely resolved and she is focused on reuniting with her son. Many of her previous delusions appear to be related to trauma and partly dissociative.

Ms. D contacts the psychologist several months later to report she is doing well in the community, staying in treatment, and working on legal means to reunite with her son. No trace of any foreign accent is detectable in her voice.

 

 

Related Resources

  • Miller N, Lowit A, O’Sullivan H. What makes acquired foreign accent syndrome foreign? Journal of Neurolinguistics. 2006; 19: 385-409.
  • Tsuruga K, Kobayashi T, Hirai N, et al. Foreign accent syndrome in a case of dissociative (conversion) disorder. Seishin Shinkeigaku Zasshi. 2008; 110(2): 79-87.

Drug Brand Names

  • Benztropine • Cogentin
  • Diphenhydramine • Benadryl
  • Divalproex • Depakote
  • Escitalopram • Lexapro
  • Haloperidol • Haldol
  • Lorazepam • Ativan
  • Risperidone • Risperdal
  • Ziprasidone • Geodon

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

CASE: Disruptive and withdrawn

Police bring Ms. D, age 33, to our psychiatric facility because of violent behavior at her group home. When confronted for allegedly stealing, she became upset, fought with a housemate, and spat. Six months before coming to our facility she was admitted to a private hospital for psychotic disorder, not otherwise specified (NOS) where she was mute, refused all food and medications, lay in her room, and covered her face with a sheet when someone tried to talk to her.

Ms. D denies having depressive symptoms, sleep disturbance, racing thoughts, thoughts of hurting herself or others, or auditory or visual hallucinations. She complains of poor appetite. Ms. D denies a history of mental illness and says she is not taking any medication. She is upset about being hospitalized and says she will not cooperate with treatment. We cannot obtain her complete psychiatric history but available records indicate that she has 1 previous psychiatric hospitalization for psychotic disorder NOS, and has received trials of haloperidol, lorazepam, diphenhydramine, escitalopram, ziprasidone, and benztropine. Her records do not indicate the dosages of these medications or how she responded to pharmacotherapy.

During her mental status exam, Ms. D is well dressed, covers her hair with a scarf, has no unusual body movements, and responds to questions appropriately. She describes her mood as “okay” but appears upset and anxious about being in the hospital. She exhibits no overt psychotic symptoms and does not appear to be responding to auditory hallucinations or having delusional thoughts. Her cognitive function is intact and her intelligence is judged to be average with impaired insight and judgment. However, she speaks with a distinct accent that sounds Jamaican; otherwise, her speech is articulate with normal rate and tone. When we ask about her accent, Ms. D, who is African American, does not disclose her ethnicity and seems to be unaware of her accent. We did not question the authenticity of her accent until after we obtained collateral information from her family.

The authors’ observations

Based on the available information, we make a provisional diagnosis of psychotic disorder NOS and Ms. D is admitted involuntarily because of concerns about her safety. She is reluctant to accept any treatment and receives an involuntary probate commitment for 90 days. At admission, Ms. D is evasive, guarded, secretive, and at times hostile. Her physical examination reveals no signs or symptoms of focal neurologic deficits. Laboratory testing, including urine toxicology, is unremarkable. She refuses an MRI. Later testing reveals a critical ammonia level of 143 μg/dL, warranting an axis III diagnosis of asymptomatic hyperammonemia.

HISTORY: Paranoia and delusions

Ms. D says she was born and raised in a southern state. She reports that she was born to an Egyptian mother who died during childbirth; her father, who is white, was an ambassador stationed abroad. Ms. D attended school until the 11thgrade and was married at age 19 to a Secret Service agent. She says she has a son who was kidnapped by her husband’s enemies, rescued by paying ransom, and currently lives with his grandfather. Ms. D is paranoid and fears that her life is in danger. She also believes that she has gluten sensitivity that could discolor and damage her hair, which is why she always keeps a scarf on her head for protection.

Through an Internet search, we find articles about Ms. D’s son’s kidnapping. The 7-year-old had been missing for weeks when police found him with his mother in safe condition in another state, after Ms. D called her mother to ask for money and a place to stay. The child was taken from Ms. D’s custody because of concerns for his safety. We also find Ms. D’s mother. Although Ms. D insists her mother is deceased, after some persuasion, she signs a release allowing us to talk to her.

Ms. D’s mother reports that her daughter’s psychiatric problems began when she was pregnant. At the time Ms. D did not have a foreign accent. She had started to “talk funny” when her psychiatric symptoms emerged after she married and became pregnant.

Foreign accent syndrome

A foreign accent can be acquired by normal phenomena, such as being immersed in a foreign language, or a pathological process,1 which can include psychiatric (functional) or neurologic illness (organic causes). Foreign accent syndrome (FAS) is a rare speech disorder characterized by the appearance of a new accent, different from the speaker’s native language, that is perceived as foreign by the listener and in most cases also by the speaker.2 Usually an FAS patient has had no exposure to the accent, although in some cases an old accent has re-emerged.3,4

 

 

FAS can result from lesions in brain areas involved in speech production, including precentral gyrus, premotor mid-frontal gyrus, left subcortical prerolandic gyrus, postrolandic gyri, and left parietal area.4 Most FAS cases are secondary to a structural lesion in the brain caused by stroke, traumatic brain injury, cerebral hemorrhage, or multiple sclerosis.2 There are a few cases in the literature of acquired foreign accent with psychogenic etiology in patients with schizophrenia and bipolar disorder with psychotic features.5

TREATMENT: Combination therapy

Based on Ms. D’s unstable mood, irritability, delusional beliefs, and paranoid ideas, we start divalproex, 500 mg/d titrated to 1, 750 mg/d, and risperidone, 3 mg in the morning and 4 mg at bedtime.

The unit psychologist evaluates Ms. D and provides individual psychotherapy, which is mainly supportive and psychoeducational. Ms. D gradually becomes cooperative and friendly. She is not willing to talk about her accent or its origin; however, as her psychiatric symptoms improve, her accent gradually diminishes. The accent never completely resolves, but reduces until it is barely noticeable.

The authors’ observations

Ms. D’s foreign accent was more prominent when she displayed positive psychotic symptoms, such as delusions and disorganized thinking, and gradually disappeared as her psychotic symptoms improved. Ms. D’s case was peculiar because her accent was 1 of the first symptoms before her psychosis fully manifested.

How are FAS and psychosis linked?

Language dysfunction in schizophrenia is common and characterized by derailment and disorganization. Severity of language dysfunction in schizophrenia is directly proportional to overall disease severity.6,7 Various hypotheses have suggested the origin of FAS. In patients with FAS secondary to a neurologic disorder, a lesion usually is found in the dominant brain hemisphere, but the cause is not clear in patients with psychosis who have normal MRI findings. One hypothesis by Reeves et al links development of FAS to the functional disconnection between the left dorsolateral prefrontal cortex (DLPFC) and the superior temporal gyrus (STG) during active psychosis.5 In normal speech production, electric impulses originate in the DLPFC and are transmitted to STG in Wernicke’s area. From there, information goes to Broca’s area, which activates the primary motor cortex to pronounce words. In healthy individuals, word generation activates the DLPFC and causes deactivation of the bilateral STG.8 In schizophrenia, the left STG fails to deactivate in the presence of activation of the left DLPFC.9 Interestingly, STG dysfunction is seen only during active phase of psychosis. Its absence in asymptomatic patients with schizophrenia and bipolar disorder10,11 suggest that a foreign accent-like syndrome may be linked to the functional disconnection between the left DLPFC and left STG dysfunction in patients with active psychosis.5

Performing functional neuroimaging, including positron-emission tomography, functional MRI, and single-photon emission computed tomography, of patients with FAS could shed more light on the possible link between FAS and psychosis. In a case report of a patient with bipolar disorder who developed FAS, MRI initially showed no structural lesion but a later functional imaging scan revealed a cerebral infarct in the left insular and anterior temporal cortex.2

One of the limitations in Ms. D’s case is the lack of neuroimaging studies. For the first few weeks of her hospitalization, it was difficult to communicate with Ms. D. She did not acknowledge her illness and would not cooperate with treatment. She was withdrawn and seemed to experience hysterical mutism, which she perceived as caused by extreme food allergies. Later, as her symptoms continued to improve with pharmacologic and psychotherapeutic interventions, neuroimaging was no longer clinically necessary.

OUTCOME: Accent disappears

As Ms. D improves, psychotherapy evolves to gently and carefully challenging her delusions and providing insight-oriented interventions and trauma therapy. As her delusions gradually start to loosen, Ms. D reveals she had been physically and emotionally abused by her husband.

At discharge after 90 days in the hospital, Ms. D’s symptoms are well managed and she no longer shows signs of a thought disorder. Her thinking is clear, rational, and logical. She demonstrates incredible insight and appreciation that she needs to stay in treatment and continue to take divalproex and risperidone. Her delusions appear to be completely resolved and she is focused on reuniting with her son. Many of her previous delusions appear to be related to trauma and partly dissociative.

Ms. D contacts the psychologist several months later to report she is doing well in the community, staying in treatment, and working on legal means to reunite with her son. No trace of any foreign accent is detectable in her voice.

 

 

Related Resources

  • Miller N, Lowit A, O’Sullivan H. What makes acquired foreign accent syndrome foreign? Journal of Neurolinguistics. 2006; 19: 385-409.
  • Tsuruga K, Kobayashi T, Hirai N, et al. Foreign accent syndrome in a case of dissociative (conversion) disorder. Seishin Shinkeigaku Zasshi. 2008; 110(2): 79-87.

Drug Brand Names

  • Benztropine • Cogentin
  • Diphenhydramine • Benadryl
  • Divalproex • Depakote
  • Escitalopram • Lexapro
  • Haloperidol • Haldol
  • Lorazepam • Ativan
  • Risperidone • Risperdal
  • Ziprasidone • Geodon

Disclosure

The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

References

1. Miller N, Lowit A, O’Sullivan H. What makes acquired foreign accent syndrome foreign? J Neurolinguistics. 2006;19(5):385-409.

2. Poulin S, Macoir J, Paquet N, et al. Psychogenic or neurogenic origin of agrammatism and foreign accent syndrome in a bipolar patient: a case report. Ann Gen Psychiatry. 2007;6:1.-

3. Takayama Y, Sugishita M, Kido T, et al. A case of foreign accent syndrome without aphasia caused by a lesion of the left precentral gyrus. Neurology. 1993;43:1361-1363.

4. Roth EJ, Fink K, Cherney LR, et al. Reversion to a previously learned foreign accent after stroke. Arch Phys Med Rehabil. 1997;78:550-552.

5. Reeves RR, Burke RS, Parker JD. Characteristics of psychotic patients with foreign accent syndrome. J Neuropsychiatry Clin Neurosci. 2007;19:70-76.

6. Ceccherini-Nelli A, Crow TJ. Disintegration of the components of language as the path to a revision of Bleuler’s and Schneider’s concepts of schizophrenia: linguistic disturbances compared with first-rank symptoms in acute psychosis. Br J Psychiatry. 2003;182:233-240.

7. Harrow M, O’Connell EM, Herbener ES, et al. Disordered verbalizations in schizophrenia: a speech disturbance or thought disorder? Compr Psychiatry. 2003;44:353-359.

8. Friston KJ, Frith CD, Liddle PF, et al. Investigating a network of word generation with positron emission tomography. Proc R Soc Lond B Biol Sci. 1991;244:101-106.

9. Frith CD, Friston K, Herold S, et al. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry. 1995;167:343-349.

10. Spence SA, Liddle PF, Stefan MD, et al. Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Focal dysfunction and distributed disconnectivity reappraised. Br J Psychiatry. 2011;176:52-60.

11. Dye SM, Spence SA, Bench CJ, et al. No evidence for left superior temporal dysfunction in asymptomatic schizophrenia and bipolar disorder. PET study of verbal fluency. Br J Psychiatry. 1999;175:367-374.

References

1. Miller N, Lowit A, O’Sullivan H. What makes acquired foreign accent syndrome foreign? J Neurolinguistics. 2006;19(5):385-409.

2. Poulin S, Macoir J, Paquet N, et al. Psychogenic or neurogenic origin of agrammatism and foreign accent syndrome in a bipolar patient: a case report. Ann Gen Psychiatry. 2007;6:1.-

3. Takayama Y, Sugishita M, Kido T, et al. A case of foreign accent syndrome without aphasia caused by a lesion of the left precentral gyrus. Neurology. 1993;43:1361-1363.

4. Roth EJ, Fink K, Cherney LR, et al. Reversion to a previously learned foreign accent after stroke. Arch Phys Med Rehabil. 1997;78:550-552.

5. Reeves RR, Burke RS, Parker JD. Characteristics of psychotic patients with foreign accent syndrome. J Neuropsychiatry Clin Neurosci. 2007;19:70-76.

6. Ceccherini-Nelli A, Crow TJ. Disintegration of the components of language as the path to a revision of Bleuler’s and Schneider’s concepts of schizophrenia: linguistic disturbances compared with first-rank symptoms in acute psychosis. Br J Psychiatry. 2003;182:233-240.

7. Harrow M, O’Connell EM, Herbener ES, et al. Disordered verbalizations in schizophrenia: a speech disturbance or thought disorder? Compr Psychiatry. 2003;44:353-359.

8. Friston KJ, Frith CD, Liddle PF, et al. Investigating a network of word generation with positron emission tomography. Proc R Soc Lond B Biol Sci. 1991;244:101-106.

9. Frith CD, Friston K, Herold S, et al. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry. 1995;167:343-349.

10. Spence SA, Liddle PF, Stefan MD, et al. Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Focal dysfunction and distributed disconnectivity reappraised. Br J Psychiatry. 2011;176:52-60.

11. Dye SM, Spence SA, Bench CJ, et al. No evidence for left superior temporal dysfunction in asymptomatic schizophrenia and bipolar disorder. PET study of verbal fluency. Br J Psychiatry. 1999;175:367-374.

Issue
Current Psychiatry - 10(03)
Issue
Current Psychiatry - 10(03)
Page Number
57-63
Page Number
57-63
Publications
Publications
Topics
Article Type
Display Headline
The mysterious foreign accent
Display Headline
The mysterious foreign accent
Legacy Keywords
foreign accent syndrome; Paul: Beckman; Bellian; Osinowo
Legacy Keywords
foreign accent syndrome; Paul: Beckman; Bellian; Osinowo
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

CT scan wasn’t ordered, diagnosis was delayed...Stroke symptoms blamed on food poisoning...

Article Type
Changed
Mon, 01/14/2019 - 11:30
Display Headline
CT scan wasn’t ordered, diagnosis was delayed...Stroke symptoms blamed on food poisoning...

CT scan wasn’t ordered, diagnosis was delayed

A 9-YEAR-OLD BOY fell and hit the left side of his head on a coffee table while playing at a friend’s house. His father, who was present, applied ice to the child’s head and took him home. The child subsequently vomited and complained that his jaw hurt. He was given ibuprofen and taken to the emergency department (ED).

The ED physician determined that he needed stitches in his left ear. After the ear was sutured, the child was discharged, even though he had vomited in the examination room.

The child vomited again around midnight, then awoke around 2:30 am and went back to sleep. Around 5:00 am he vomited again and was gasping for air and breathing with difficulty. A call to 911 resulted in the child being airlifted to a trauma center, where a computed tomography (CT) scan revealed a massive hematoma. The brain was herniated and protruding from the bottom of the skull.

After undergoing emergency surgery, the patient spent 3 days in the ICU, some of that time on a ventilator, and several weeks in the hospital. After discharge, he underwent intensive therapy to relearn how to eat and talk. He suffered cognitive losses, emotional difficulties, left-sided weakness, and hemiparesis.

PLAINTIFF’S CLAIM The ED physician should have ordered a CT scan, which would have revealed the hematoma and prompted emergency surgery to relieve the pressure. The physician didn’t tell the parents how to observe the child for a head injury.

THE DEFENSE A CT scan wasn’t necessary. The patient appeared fine in the ED and was neurologically intact with a perfect Glasgow coma score of 15. Hematoma was a low possibility. The parents were told to watch the child and received head injury instructions.

VERDICT $2.4 million Ohio verdict.

COMMENT A variety of decision support tools would suggest CT in the face of vomiting 2 or more times, even with a Glasgow coma score of 15 (see the discussion of the Canadian CT Head Rule and New Orleans Criteria at http://guidelines.gov/content.aspx?id=136&search=neuroimaging+children+head+trauma). Clinical judgment alone may be insufficient to detect potentially catastrophic injury—particularly in younger children.

Stroke symptoms blamed on food poisoning

AN ISCHEMIC, LEFT-SIDED STROKE with left inferior frontoparietal lobe, occipital lobe, and cerebellar infarcts left a 33-year-old man with unclear speech, difficulty walking, major headache, and other stroke symptoms. He was taken by ambulance to a hospital within 1 hour of the onset of symptoms.

Hospital staff diagnosed food poisoning and discharged the man even though he couldn’t walk or speak coherently. The patient suffered brain damage resulting in cognitive impairment with memory loss and confusion.

PLAINTIFF’S CLAIM A proper neurologic work-up wasn’t done; hospital staff should have consulted a neurologist. The patient should have received tissue plasminogen activator (t-PA).

THE DEFENSE The history provided at the hospital mentioned that the patient had eaten chocolate cake before the onset of symptoms; the symptoms weren’t significant enough to consider stroke in the differential diagnosis. The plaintiff couldn’t prove that his condition would have been significantly better even if he’d received t-PA.

VERDICT $2.1 million California arbitration award.

COMMENT This story is difficult to believe—food poisoning causing trouble speaking, difficulty walking, and a headache?! One can only wonder whether better documentation of medical decision making would have produced a more understandable response.

Article PDF
Author and Disclosure Information

COMMENTARY PROVIDED BY
Jeffrey L. Susman, MD
Editor-in-Chief

Issue
The Journal of Family Practice - 60(3)
Publications
Topics
Page Number
163-163
Legacy Keywords
Jeffrey L. Susman; CT scan; food poisoning; medical judgments and settlements
Sections
Author and Disclosure Information

COMMENTARY PROVIDED BY
Jeffrey L. Susman, MD
Editor-in-Chief

Author and Disclosure Information

COMMENTARY PROVIDED BY
Jeffrey L. Susman, MD
Editor-in-Chief

Article PDF
Article PDF

CT scan wasn’t ordered, diagnosis was delayed

A 9-YEAR-OLD BOY fell and hit the left side of his head on a coffee table while playing at a friend’s house. His father, who was present, applied ice to the child’s head and took him home. The child subsequently vomited and complained that his jaw hurt. He was given ibuprofen and taken to the emergency department (ED).

The ED physician determined that he needed stitches in his left ear. After the ear was sutured, the child was discharged, even though he had vomited in the examination room.

The child vomited again around midnight, then awoke around 2:30 am and went back to sleep. Around 5:00 am he vomited again and was gasping for air and breathing with difficulty. A call to 911 resulted in the child being airlifted to a trauma center, where a computed tomography (CT) scan revealed a massive hematoma. The brain was herniated and protruding from the bottom of the skull.

After undergoing emergency surgery, the patient spent 3 days in the ICU, some of that time on a ventilator, and several weeks in the hospital. After discharge, he underwent intensive therapy to relearn how to eat and talk. He suffered cognitive losses, emotional difficulties, left-sided weakness, and hemiparesis.

PLAINTIFF’S CLAIM The ED physician should have ordered a CT scan, which would have revealed the hematoma and prompted emergency surgery to relieve the pressure. The physician didn’t tell the parents how to observe the child for a head injury.

THE DEFENSE A CT scan wasn’t necessary. The patient appeared fine in the ED and was neurologically intact with a perfect Glasgow coma score of 15. Hematoma was a low possibility. The parents were told to watch the child and received head injury instructions.

VERDICT $2.4 million Ohio verdict.

COMMENT A variety of decision support tools would suggest CT in the face of vomiting 2 or more times, even with a Glasgow coma score of 15 (see the discussion of the Canadian CT Head Rule and New Orleans Criteria at http://guidelines.gov/content.aspx?id=136&search=neuroimaging+children+head+trauma). Clinical judgment alone may be insufficient to detect potentially catastrophic injury—particularly in younger children.

Stroke symptoms blamed on food poisoning

AN ISCHEMIC, LEFT-SIDED STROKE with left inferior frontoparietal lobe, occipital lobe, and cerebellar infarcts left a 33-year-old man with unclear speech, difficulty walking, major headache, and other stroke symptoms. He was taken by ambulance to a hospital within 1 hour of the onset of symptoms.

Hospital staff diagnosed food poisoning and discharged the man even though he couldn’t walk or speak coherently. The patient suffered brain damage resulting in cognitive impairment with memory loss and confusion.

PLAINTIFF’S CLAIM A proper neurologic work-up wasn’t done; hospital staff should have consulted a neurologist. The patient should have received tissue plasminogen activator (t-PA).

THE DEFENSE The history provided at the hospital mentioned that the patient had eaten chocolate cake before the onset of symptoms; the symptoms weren’t significant enough to consider stroke in the differential diagnosis. The plaintiff couldn’t prove that his condition would have been significantly better even if he’d received t-PA.

VERDICT $2.1 million California arbitration award.

COMMENT This story is difficult to believe—food poisoning causing trouble speaking, difficulty walking, and a headache?! One can only wonder whether better documentation of medical decision making would have produced a more understandable response.

CT scan wasn’t ordered, diagnosis was delayed

A 9-YEAR-OLD BOY fell and hit the left side of his head on a coffee table while playing at a friend’s house. His father, who was present, applied ice to the child’s head and took him home. The child subsequently vomited and complained that his jaw hurt. He was given ibuprofen and taken to the emergency department (ED).

The ED physician determined that he needed stitches in his left ear. After the ear was sutured, the child was discharged, even though he had vomited in the examination room.

The child vomited again around midnight, then awoke around 2:30 am and went back to sleep. Around 5:00 am he vomited again and was gasping for air and breathing with difficulty. A call to 911 resulted in the child being airlifted to a trauma center, where a computed tomography (CT) scan revealed a massive hematoma. The brain was herniated and protruding from the bottom of the skull.

After undergoing emergency surgery, the patient spent 3 days in the ICU, some of that time on a ventilator, and several weeks in the hospital. After discharge, he underwent intensive therapy to relearn how to eat and talk. He suffered cognitive losses, emotional difficulties, left-sided weakness, and hemiparesis.

PLAINTIFF’S CLAIM The ED physician should have ordered a CT scan, which would have revealed the hematoma and prompted emergency surgery to relieve the pressure. The physician didn’t tell the parents how to observe the child for a head injury.

THE DEFENSE A CT scan wasn’t necessary. The patient appeared fine in the ED and was neurologically intact with a perfect Glasgow coma score of 15. Hematoma was a low possibility. The parents were told to watch the child and received head injury instructions.

VERDICT $2.4 million Ohio verdict.

COMMENT A variety of decision support tools would suggest CT in the face of vomiting 2 or more times, even with a Glasgow coma score of 15 (see the discussion of the Canadian CT Head Rule and New Orleans Criteria at http://guidelines.gov/content.aspx?id=136&search=neuroimaging+children+head+trauma). Clinical judgment alone may be insufficient to detect potentially catastrophic injury—particularly in younger children.

Stroke symptoms blamed on food poisoning

AN ISCHEMIC, LEFT-SIDED STROKE with left inferior frontoparietal lobe, occipital lobe, and cerebellar infarcts left a 33-year-old man with unclear speech, difficulty walking, major headache, and other stroke symptoms. He was taken by ambulance to a hospital within 1 hour of the onset of symptoms.

Hospital staff diagnosed food poisoning and discharged the man even though he couldn’t walk or speak coherently. The patient suffered brain damage resulting in cognitive impairment with memory loss and confusion.

PLAINTIFF’S CLAIM A proper neurologic work-up wasn’t done; hospital staff should have consulted a neurologist. The patient should have received tissue plasminogen activator (t-PA).

THE DEFENSE The history provided at the hospital mentioned that the patient had eaten chocolate cake before the onset of symptoms; the symptoms weren’t significant enough to consider stroke in the differential diagnosis. The plaintiff couldn’t prove that his condition would have been significantly better even if he’d received t-PA.

VERDICT $2.1 million California arbitration award.

COMMENT This story is difficult to believe—food poisoning causing trouble speaking, difficulty walking, and a headache?! One can only wonder whether better documentation of medical decision making would have produced a more understandable response.

Issue
The Journal of Family Practice - 60(3)
Issue
The Journal of Family Practice - 60(3)
Page Number
163-163
Page Number
163-163
Publications
Publications
Topics
Article Type
Display Headline
CT scan wasn’t ordered, diagnosis was delayed...Stroke symptoms blamed on food poisoning...
Display Headline
CT scan wasn’t ordered, diagnosis was delayed...Stroke symptoms blamed on food poisoning...
Legacy Keywords
Jeffrey L. Susman; CT scan; food poisoning; medical judgments and settlements
Legacy Keywords
Jeffrey L. Susman; CT scan; food poisoning; medical judgments and settlements
Sections
Disallow All Ads
Article PDF Media

CDC update: Guidelines for treating STDs

Article Type
Changed
Wed, 03/27/2019 - 13:04
Display Headline
CDC update: Guidelines for treating STDs

In 2010, the CDC released an update of its Sexually Transmitted Diseases (STD) Treatment Guidelines,1 which were last updated in 2006. The guidelines are widely viewed as the most authoritative source of information on the diagnosis, treatment, and follow-up of STDs, and they are the standard for publicly and privately funded clinics focusing on sexual health.

What’s new

Some of the notable changes made since the last update in 2006 appear in TABLE 1.1,2

Uncomplicated gonorrhea. Cephalosporins are the only class of antibiotic recommended as first-line treatment for gonorrhea. (In a 2007 recommendation revision, the CDC opted to no longer recommend quinolone antibiotics for the treatment of gonorrhea, because of widespread bacterial resistance.3) Preference is now given to ceftriaxone because of its proven effectiveness against pharyngeal infection, which is often asymptomatic, difficult to detect, and difficult to eradicate. Additionally, the 2010 update has increased the recommended dose of ceftriazone from 125 to 250 mg intramuscularly. The larger dose is more effective against pharyngeal infection; it is also a safeguard against decreased bacterial susceptibility to cephalosporins, which, although still very low, has been reported in more cases recently.

The guidelines still recommend that azithromycin, 1 g orally in a single dose, be given with ceftriaxone because of the relatively high rate of co-infection with Chlamydia trachomatis and the potential for azithromycin to assist with eradicating any gonorrhea with decreased susceptibility to ceftriaxone.

Pelvic inflammatory disease. Quinolones have also been removed from the list of options for outpatient treatment of pelvic inflammatory disease. All recommended regimens now specify a parenteral cephalosporin as a single injection with doxycycline 100 mg PO twice a day for 14 days, with or without metronidazole 500 mg PO twice a day for 14 days.

Bacterial vaginosis. Tinidazole, 2 g orally once a day for 2 days or 1 g orally once a day for 5 days, is now an alternative agent for bacterial vaginosis. However, preferred treatments remain metronidazole 500 mg orally twice a day for 7 days, metronidazole gel intravaginally once a day for 5 days, or clindamycin cream intravaginally at bedtime for 7 days.

Newborn gonococcal eye infection. A relatively minor change is the elimination of tetracycline as prophylaxis for newborn gonococcal eye infections, leaving only erythromycin ointment to prevent the condition.

TABLE 1
2010 vs 2006: How have the CDC recommendations for STD treatment changed?
1,2

Uncomplicated gonococcal infections of the cervix, urethra, rectum, and pharynx
  • Ceftriaxone IM dose increased from 125 to 250 mg
  • Quinolones no longer recommended
Pelvic inflammatory disease
Parenteral regimens
  • Quinolones no longer recommended
Outpatient regimens
  • Quinolones no longer recommended
  • Completely oral regimens no longer recommended; all include an injectable cephalosporin
Bacterial vaginosis
  • Tinidazole now an alternative agent; however,
  • Metronidazole orally, metronidazole intravaginally, or clindamycin intravaginally still preferred
Prophylaxis for gonococcal eye infection in a newborn
  • Tetracycline ointment no longer recommended
  • Erythromycin ointment the only recommended regimen

Single-dose therapy preferred among equivalent options

Single-dose therapy (TABLE 2), while often more expensive than other options, increases compliance and helps ensure treatment completion. Single-dose therapy administered in your office is essentially directly observed treatment, an intervention that has become the standard of care for other diseases such as tuberculosis. If the single-dose agent is as effective as alternative medications, directly observed on-site administration is the preferred option for treating STDs.

TABLE 2
Single-dose therapies for specific STDs
1

Infection or conditionSingle-dose therapy
CandidaMiconazole 1200 mg vaginal suppository
  or
Tioconazole 6.5% ointment 5 g intravaginally
  or
Butoconazole 2% cream 5 g intravaginally
  or
Fluconazole 150 mg PO
CervicitisAzithromycin 1 g PO
ChancroidAzithromycin 1 g PO
  or
Ceftriaxone 250 mg IM
Chlamydia urogenital infectionAzithromycin 1 g PO
Gonorrhea: conjunctivitisCeftriaxone 1 g IM
Gonorrhea: uncomplicated infection of the cervix, urethra, rectumCeftriaxone 250 mg IM (preferred)
  or
Cefixime 400 mg PO
  or
Single-dose injectable cephalosporin plus Azithromycin 1 g PO
Gonorrhea: uncomplicated infection of the pharynxCeftriaxone 250 mg IM
  plus
Azithromycin 1 g PO
Nongonococcal urethritisAzithromycin 1 g PO
Post-sexual assault prophylaxisCeftriaxone 250 mg IM
  or
Cefixime 400 mg PO
  plus
Metronidazole 2 g PO
  plus
Azithromycin 1 g PO
Recurrent, persistent nongonococcal urethritisMetronidazole 2 g PO
  or
Tinidazole 2 g PO
  plus
Azithromycin 1 g PO (if not used for initial episode)
Syphilis: primary, secondary, and early latentBenzathine penicillin G 2.4 million units IM
TrichomoniasisMetronidazole 2 g PO
  or
Tinidazole 2 g PO

Other guideline recommendations
The CDC’s STD treatment guidelines contain a wealth of useful information beyond treatment advice: recommended methods of confirming diagnoses, analyses of the usefulness of various diagnostic tests, recommendations on how to manage sex partners of those infected, guidance on STD prevention counseling, and considerations for special populations and circumstances.

 

 

Additionally, there is a section on screening for STDs reflecting recommendations of the US Preventive Services Task Force (USPSTF); it also includes recommendations from the American College of Obstetricians and Gynecologists. In at least one instance, though, the USPSTF recommendation on screening for HIV infection contradicts other CDC sources.4,5 Also included is guidance on using vaccines to prevent hepatitis A, hepatitis B, and human papillomavirus (HPV), which follows the recommendations of the Advisory Committee on Immunization Practices. When to use DNA testing to detect HPV is described briefly.

A shortcoming of the CDC guidelines
Although the CDC’s STD guidelines remain the most authoritative source of information on the diagnosis and treatment of STDs, they do not seem to use a consistent method for assessing and describing the strength of the evidence behind the recommendations, which family physicians have come to expect. (However, it is sometimes possible to discern the type and strength of evidence for a particular recommendation from the written discussion.)

The new guidelines state that a series of papers to be published in Clinical Infectious Diseases will describe more fully the evidence behind some of the recommendations and include evidence tables. However, in future guideline updates, it would be helpful if the CDC were to include a brief description of the quantity and strength of evidence alongside each recommended treatment option in the tables.

How best to keep up to date
Although the new guidelines summarize the current status of recommendations on the diagnosis, treatment, and prevention of STDs and are a useful resource for family physicians, we cannot stay current simply by referring to them alone over the next 4 to 5 years until a new edition is published. As new evidence develops, changes in recommendations will be published in the Morbidity and Mortality Weekly Report.

Case in point: new interim HIV recommendations. Interim recommendations were recently released on pre-exposure prophylaxis for men who have sex with men.6 (For more on these recommendations, check out this month’s audiocast at jfponline.com.) Final recommendations are expected later this year. Recommendations for post-exposure prophylaxis to prevent HIV infection are also expected soon.

References

1. Workowski KA, Berman S. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.

2. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1-94.

3. Campos-Outcalt D. Practice alert: CDC no longer recommends quinolones for treatment of gonorrhea. J Fam Pract. 2007;56:554-558.

4. Branson BM, Handsfield HH, Lampe MA, et al. for the Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.

5. Campos-Outcalt D. Time to revise your HIV testing routine. J Fam Pract. 2007;56:283-284.

6. Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68.

Article PDF
Author and Disclosure Information

New CDC guidance on pre-exposure HIV prophylaxis for men who have sex with men
Doug Campos-Outcalt, MD, MPA

Doug Campos-Outcalt, MD, MPA
Department of Family and Community Medicine, University of Arizona College of Medicine, Phoenix
[email protected]

Issue
The Journal of Family Practice - 60(3)
Publications
Topics
Page Number
143-146
Legacy Keywords
Doug Campos-Outcalt; treating STDs; pre-exposure HIV prophylaxis; men who have sex with men; ceftriaxone; bacterial vaginosis
Sections
Author and Disclosure Information

New CDC guidance on pre-exposure HIV prophylaxis for men who have sex with men
Doug Campos-Outcalt, MD, MPA

Doug Campos-Outcalt, MD, MPA
Department of Family and Community Medicine, University of Arizona College of Medicine, Phoenix
[email protected]

Author and Disclosure Information

New CDC guidance on pre-exposure HIV prophylaxis for men who have sex with men
Doug Campos-Outcalt, MD, MPA

Doug Campos-Outcalt, MD, MPA
Department of Family and Community Medicine, University of Arizona College of Medicine, Phoenix
[email protected]

Article PDF
Article PDF

In 2010, the CDC released an update of its Sexually Transmitted Diseases (STD) Treatment Guidelines,1 which were last updated in 2006. The guidelines are widely viewed as the most authoritative source of information on the diagnosis, treatment, and follow-up of STDs, and they are the standard for publicly and privately funded clinics focusing on sexual health.

What’s new

Some of the notable changes made since the last update in 2006 appear in TABLE 1.1,2

Uncomplicated gonorrhea. Cephalosporins are the only class of antibiotic recommended as first-line treatment for gonorrhea. (In a 2007 recommendation revision, the CDC opted to no longer recommend quinolone antibiotics for the treatment of gonorrhea, because of widespread bacterial resistance.3) Preference is now given to ceftriaxone because of its proven effectiveness against pharyngeal infection, which is often asymptomatic, difficult to detect, and difficult to eradicate. Additionally, the 2010 update has increased the recommended dose of ceftriazone from 125 to 250 mg intramuscularly. The larger dose is more effective against pharyngeal infection; it is also a safeguard against decreased bacterial susceptibility to cephalosporins, which, although still very low, has been reported in more cases recently.

The guidelines still recommend that azithromycin, 1 g orally in a single dose, be given with ceftriaxone because of the relatively high rate of co-infection with Chlamydia trachomatis and the potential for azithromycin to assist with eradicating any gonorrhea with decreased susceptibility to ceftriaxone.

Pelvic inflammatory disease. Quinolones have also been removed from the list of options for outpatient treatment of pelvic inflammatory disease. All recommended regimens now specify a parenteral cephalosporin as a single injection with doxycycline 100 mg PO twice a day for 14 days, with or without metronidazole 500 mg PO twice a day for 14 days.

Bacterial vaginosis. Tinidazole, 2 g orally once a day for 2 days or 1 g orally once a day for 5 days, is now an alternative agent for bacterial vaginosis. However, preferred treatments remain metronidazole 500 mg orally twice a day for 7 days, metronidazole gel intravaginally once a day for 5 days, or clindamycin cream intravaginally at bedtime for 7 days.

Newborn gonococcal eye infection. A relatively minor change is the elimination of tetracycline as prophylaxis for newborn gonococcal eye infections, leaving only erythromycin ointment to prevent the condition.

TABLE 1
2010 vs 2006: How have the CDC recommendations for STD treatment changed?
1,2

Uncomplicated gonococcal infections of the cervix, urethra, rectum, and pharynx
  • Ceftriaxone IM dose increased from 125 to 250 mg
  • Quinolones no longer recommended
Pelvic inflammatory disease
Parenteral regimens
  • Quinolones no longer recommended
Outpatient regimens
  • Quinolones no longer recommended
  • Completely oral regimens no longer recommended; all include an injectable cephalosporin
Bacterial vaginosis
  • Tinidazole now an alternative agent; however,
  • Metronidazole orally, metronidazole intravaginally, or clindamycin intravaginally still preferred
Prophylaxis for gonococcal eye infection in a newborn
  • Tetracycline ointment no longer recommended
  • Erythromycin ointment the only recommended regimen

Single-dose therapy preferred among equivalent options

Single-dose therapy (TABLE 2), while often more expensive than other options, increases compliance and helps ensure treatment completion. Single-dose therapy administered in your office is essentially directly observed treatment, an intervention that has become the standard of care for other diseases such as tuberculosis. If the single-dose agent is as effective as alternative medications, directly observed on-site administration is the preferred option for treating STDs.

TABLE 2
Single-dose therapies for specific STDs
1

Infection or conditionSingle-dose therapy
CandidaMiconazole 1200 mg vaginal suppository
  or
Tioconazole 6.5% ointment 5 g intravaginally
  or
Butoconazole 2% cream 5 g intravaginally
  or
Fluconazole 150 mg PO
CervicitisAzithromycin 1 g PO
ChancroidAzithromycin 1 g PO
  or
Ceftriaxone 250 mg IM
Chlamydia urogenital infectionAzithromycin 1 g PO
Gonorrhea: conjunctivitisCeftriaxone 1 g IM
Gonorrhea: uncomplicated infection of the cervix, urethra, rectumCeftriaxone 250 mg IM (preferred)
  or
Cefixime 400 mg PO
  or
Single-dose injectable cephalosporin plus Azithromycin 1 g PO
Gonorrhea: uncomplicated infection of the pharynxCeftriaxone 250 mg IM
  plus
Azithromycin 1 g PO
Nongonococcal urethritisAzithromycin 1 g PO
Post-sexual assault prophylaxisCeftriaxone 250 mg IM
  or
Cefixime 400 mg PO
  plus
Metronidazole 2 g PO
  plus
Azithromycin 1 g PO
Recurrent, persistent nongonococcal urethritisMetronidazole 2 g PO
  or
Tinidazole 2 g PO
  plus
Azithromycin 1 g PO (if not used for initial episode)
Syphilis: primary, secondary, and early latentBenzathine penicillin G 2.4 million units IM
TrichomoniasisMetronidazole 2 g PO
  or
Tinidazole 2 g PO

Other guideline recommendations
The CDC’s STD treatment guidelines contain a wealth of useful information beyond treatment advice: recommended methods of confirming diagnoses, analyses of the usefulness of various diagnostic tests, recommendations on how to manage sex partners of those infected, guidance on STD prevention counseling, and considerations for special populations and circumstances.

 

 

Additionally, there is a section on screening for STDs reflecting recommendations of the US Preventive Services Task Force (USPSTF); it also includes recommendations from the American College of Obstetricians and Gynecologists. In at least one instance, though, the USPSTF recommendation on screening for HIV infection contradicts other CDC sources.4,5 Also included is guidance on using vaccines to prevent hepatitis A, hepatitis B, and human papillomavirus (HPV), which follows the recommendations of the Advisory Committee on Immunization Practices. When to use DNA testing to detect HPV is described briefly.

A shortcoming of the CDC guidelines
Although the CDC’s STD guidelines remain the most authoritative source of information on the diagnosis and treatment of STDs, they do not seem to use a consistent method for assessing and describing the strength of the evidence behind the recommendations, which family physicians have come to expect. (However, it is sometimes possible to discern the type and strength of evidence for a particular recommendation from the written discussion.)

The new guidelines state that a series of papers to be published in Clinical Infectious Diseases will describe more fully the evidence behind some of the recommendations and include evidence tables. However, in future guideline updates, it would be helpful if the CDC were to include a brief description of the quantity and strength of evidence alongside each recommended treatment option in the tables.

How best to keep up to date
Although the new guidelines summarize the current status of recommendations on the diagnosis, treatment, and prevention of STDs and are a useful resource for family physicians, we cannot stay current simply by referring to them alone over the next 4 to 5 years until a new edition is published. As new evidence develops, changes in recommendations will be published in the Morbidity and Mortality Weekly Report.

Case in point: new interim HIV recommendations. Interim recommendations were recently released on pre-exposure prophylaxis for men who have sex with men.6 (For more on these recommendations, check out this month’s audiocast at jfponline.com.) Final recommendations are expected later this year. Recommendations for post-exposure prophylaxis to prevent HIV infection are also expected soon.

In 2010, the CDC released an update of its Sexually Transmitted Diseases (STD) Treatment Guidelines,1 which were last updated in 2006. The guidelines are widely viewed as the most authoritative source of information on the diagnosis, treatment, and follow-up of STDs, and they are the standard for publicly and privately funded clinics focusing on sexual health.

What’s new

Some of the notable changes made since the last update in 2006 appear in TABLE 1.1,2

Uncomplicated gonorrhea. Cephalosporins are the only class of antibiotic recommended as first-line treatment for gonorrhea. (In a 2007 recommendation revision, the CDC opted to no longer recommend quinolone antibiotics for the treatment of gonorrhea, because of widespread bacterial resistance.3) Preference is now given to ceftriaxone because of its proven effectiveness against pharyngeal infection, which is often asymptomatic, difficult to detect, and difficult to eradicate. Additionally, the 2010 update has increased the recommended dose of ceftriazone from 125 to 250 mg intramuscularly. The larger dose is more effective against pharyngeal infection; it is also a safeguard against decreased bacterial susceptibility to cephalosporins, which, although still very low, has been reported in more cases recently.

The guidelines still recommend that azithromycin, 1 g orally in a single dose, be given with ceftriaxone because of the relatively high rate of co-infection with Chlamydia trachomatis and the potential for azithromycin to assist with eradicating any gonorrhea with decreased susceptibility to ceftriaxone.

Pelvic inflammatory disease. Quinolones have also been removed from the list of options for outpatient treatment of pelvic inflammatory disease. All recommended regimens now specify a parenteral cephalosporin as a single injection with doxycycline 100 mg PO twice a day for 14 days, with or without metronidazole 500 mg PO twice a day for 14 days.

Bacterial vaginosis. Tinidazole, 2 g orally once a day for 2 days or 1 g orally once a day for 5 days, is now an alternative agent for bacterial vaginosis. However, preferred treatments remain metronidazole 500 mg orally twice a day for 7 days, metronidazole gel intravaginally once a day for 5 days, or clindamycin cream intravaginally at bedtime for 7 days.

Newborn gonococcal eye infection. A relatively minor change is the elimination of tetracycline as prophylaxis for newborn gonococcal eye infections, leaving only erythromycin ointment to prevent the condition.

TABLE 1
2010 vs 2006: How have the CDC recommendations for STD treatment changed?
1,2

Uncomplicated gonococcal infections of the cervix, urethra, rectum, and pharynx
  • Ceftriaxone IM dose increased from 125 to 250 mg
  • Quinolones no longer recommended
Pelvic inflammatory disease
Parenteral regimens
  • Quinolones no longer recommended
Outpatient regimens
  • Quinolones no longer recommended
  • Completely oral regimens no longer recommended; all include an injectable cephalosporin
Bacterial vaginosis
  • Tinidazole now an alternative agent; however,
  • Metronidazole orally, metronidazole intravaginally, or clindamycin intravaginally still preferred
Prophylaxis for gonococcal eye infection in a newborn
  • Tetracycline ointment no longer recommended
  • Erythromycin ointment the only recommended regimen

Single-dose therapy preferred among equivalent options

Single-dose therapy (TABLE 2), while often more expensive than other options, increases compliance and helps ensure treatment completion. Single-dose therapy administered in your office is essentially directly observed treatment, an intervention that has become the standard of care for other diseases such as tuberculosis. If the single-dose agent is as effective as alternative medications, directly observed on-site administration is the preferred option for treating STDs.

TABLE 2
Single-dose therapies for specific STDs
1

Infection or conditionSingle-dose therapy
CandidaMiconazole 1200 mg vaginal suppository
  or
Tioconazole 6.5% ointment 5 g intravaginally
  or
Butoconazole 2% cream 5 g intravaginally
  or
Fluconazole 150 mg PO
CervicitisAzithromycin 1 g PO
ChancroidAzithromycin 1 g PO
  or
Ceftriaxone 250 mg IM
Chlamydia urogenital infectionAzithromycin 1 g PO
Gonorrhea: conjunctivitisCeftriaxone 1 g IM
Gonorrhea: uncomplicated infection of the cervix, urethra, rectumCeftriaxone 250 mg IM (preferred)
  or
Cefixime 400 mg PO
  or
Single-dose injectable cephalosporin plus Azithromycin 1 g PO
Gonorrhea: uncomplicated infection of the pharynxCeftriaxone 250 mg IM
  plus
Azithromycin 1 g PO
Nongonococcal urethritisAzithromycin 1 g PO
Post-sexual assault prophylaxisCeftriaxone 250 mg IM
  or
Cefixime 400 mg PO
  plus
Metronidazole 2 g PO
  plus
Azithromycin 1 g PO
Recurrent, persistent nongonococcal urethritisMetronidazole 2 g PO
  or
Tinidazole 2 g PO
  plus
Azithromycin 1 g PO (if not used for initial episode)
Syphilis: primary, secondary, and early latentBenzathine penicillin G 2.4 million units IM
TrichomoniasisMetronidazole 2 g PO
  or
Tinidazole 2 g PO

Other guideline recommendations
The CDC’s STD treatment guidelines contain a wealth of useful information beyond treatment advice: recommended methods of confirming diagnoses, analyses of the usefulness of various diagnostic tests, recommendations on how to manage sex partners of those infected, guidance on STD prevention counseling, and considerations for special populations and circumstances.

 

 

Additionally, there is a section on screening for STDs reflecting recommendations of the US Preventive Services Task Force (USPSTF); it also includes recommendations from the American College of Obstetricians and Gynecologists. In at least one instance, though, the USPSTF recommendation on screening for HIV infection contradicts other CDC sources.4,5 Also included is guidance on using vaccines to prevent hepatitis A, hepatitis B, and human papillomavirus (HPV), which follows the recommendations of the Advisory Committee on Immunization Practices. When to use DNA testing to detect HPV is described briefly.

A shortcoming of the CDC guidelines
Although the CDC’s STD guidelines remain the most authoritative source of information on the diagnosis and treatment of STDs, they do not seem to use a consistent method for assessing and describing the strength of the evidence behind the recommendations, which family physicians have come to expect. (However, it is sometimes possible to discern the type and strength of evidence for a particular recommendation from the written discussion.)

The new guidelines state that a series of papers to be published in Clinical Infectious Diseases will describe more fully the evidence behind some of the recommendations and include evidence tables. However, in future guideline updates, it would be helpful if the CDC were to include a brief description of the quantity and strength of evidence alongside each recommended treatment option in the tables.

How best to keep up to date
Although the new guidelines summarize the current status of recommendations on the diagnosis, treatment, and prevention of STDs and are a useful resource for family physicians, we cannot stay current simply by referring to them alone over the next 4 to 5 years until a new edition is published. As new evidence develops, changes in recommendations will be published in the Morbidity and Mortality Weekly Report.

Case in point: new interim HIV recommendations. Interim recommendations were recently released on pre-exposure prophylaxis for men who have sex with men.6 (For more on these recommendations, check out this month’s audiocast at jfponline.com.) Final recommendations are expected later this year. Recommendations for post-exposure prophylaxis to prevent HIV infection are also expected soon.

References

1. Workowski KA, Berman S. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.

2. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1-94.

3. Campos-Outcalt D. Practice alert: CDC no longer recommends quinolones for treatment of gonorrhea. J Fam Pract. 2007;56:554-558.

4. Branson BM, Handsfield HH, Lampe MA, et al. for the Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.

5. Campos-Outcalt D. Time to revise your HIV testing routine. J Fam Pract. 2007;56:283-284.

6. Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68.

References

1. Workowski KA, Berman S. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.

2. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1-94.

3. Campos-Outcalt D. Practice alert: CDC no longer recommends quinolones for treatment of gonorrhea. J Fam Pract. 2007;56:554-558.

4. Branson BM, Handsfield HH, Lampe MA, et al. for the Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.

5. Campos-Outcalt D. Time to revise your HIV testing routine. J Fam Pract. 2007;56:283-284.

6. Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68.

Issue
The Journal of Family Practice - 60(3)
Issue
The Journal of Family Practice - 60(3)
Page Number
143-146
Page Number
143-146
Publications
Publications
Topics
Article Type
Display Headline
CDC update: Guidelines for treating STDs
Display Headline
CDC update: Guidelines for treating STDs
Legacy Keywords
Doug Campos-Outcalt; treating STDs; pre-exposure HIV prophylaxis; men who have sex with men; ceftriaxone; bacterial vaginosis
Legacy Keywords
Doug Campos-Outcalt; treating STDs; pre-exposure HIV prophylaxis; men who have sex with men; ceftriaxone; bacterial vaginosis
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Urine drug testing: An unproven risk management tool?

Article Type
Changed
Mon, 01/14/2019 - 11:30
Display Headline
Urine drug testing: An unproven risk management tool?

As a member of the editorial board of the Journal of Pain & Palliative Care Pharmacotherapy, an author of numerous scholarly articles about chronic pain (some of which are cited here), and a person who lives with chronic pain, I would like to comment on “Is it time to drug test your chronic pain patient?” (J Fam Pract. 2010;59:628-633). Drs. McBane and Weigle recommend the use of pain agreements and drug testing for every patient with noncancer chronic pain, but fail to mention that there is insufficient evidence of the efficacy of both adherence monitoring tools.1 In addition, a recent article in The American Journal of Bioethics recommends against the “universal application of pain agreements” and suggests that they can harm the patient/physician relationship.2 Consent for drug testing often comes from the pain contract3—agreements that have been called “unconscionable adhesion contracts” and may be unenforceable.4

The authors also suggest that urine drug testing is noninvasive. Nothing could be further from the truth. Drug testing of people with pain may be considered a suspicionless and warrantless search of bodily fluids and in certain cases may be unconstitutional.5 There is no question that drug misuse, abuse, addiction, and overdose are devastating to individuals, families, and society. However, using unproven risk management tools that may cause greater harm than good is just bad medicine.

Mark Collen
Sacramento, Calif

References

1. Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152:712-720.

2. Payne R, Anderson E, Arnold R, et al. A rose by any other name: pain contracts/agreements. Am J Bioeth. 2010;10:5-12.

3. Collen M. Analysis of controlled substance agreements from private practice physicians. J Pain Palliat Care Pharmacother. 2009;23:357-364.

4. Collen M. Opioid contracts and random drug testing for people with chronic pain—think twice. J Law Med Ethics. 2009;37:841-845.

5. Collen M. The Fourth Amendment and random drug testing of people with chronic pain. J Pain Palliat Care Pharmacother. 2011;25:in press.

Article PDF
Author and Disclosure Information

Issue
The Journal of Family Practice - 60(3)
Publications
Topics
Page Number
120-121
Legacy Keywords
Mark Collen; urine drug testing; consent for drug testing; pain contract; unproven risk management
Sections
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

As a member of the editorial board of the Journal of Pain & Palliative Care Pharmacotherapy, an author of numerous scholarly articles about chronic pain (some of which are cited here), and a person who lives with chronic pain, I would like to comment on “Is it time to drug test your chronic pain patient?” (J Fam Pract. 2010;59:628-633). Drs. McBane and Weigle recommend the use of pain agreements and drug testing for every patient with noncancer chronic pain, but fail to mention that there is insufficient evidence of the efficacy of both adherence monitoring tools.1 In addition, a recent article in The American Journal of Bioethics recommends against the “universal application of pain agreements” and suggests that they can harm the patient/physician relationship.2 Consent for drug testing often comes from the pain contract3—agreements that have been called “unconscionable adhesion contracts” and may be unenforceable.4

The authors also suggest that urine drug testing is noninvasive. Nothing could be further from the truth. Drug testing of people with pain may be considered a suspicionless and warrantless search of bodily fluids and in certain cases may be unconstitutional.5 There is no question that drug misuse, abuse, addiction, and overdose are devastating to individuals, families, and society. However, using unproven risk management tools that may cause greater harm than good is just bad medicine.

Mark Collen
Sacramento, Calif

As a member of the editorial board of the Journal of Pain & Palliative Care Pharmacotherapy, an author of numerous scholarly articles about chronic pain (some of which are cited here), and a person who lives with chronic pain, I would like to comment on “Is it time to drug test your chronic pain patient?” (J Fam Pract. 2010;59:628-633). Drs. McBane and Weigle recommend the use of pain agreements and drug testing for every patient with noncancer chronic pain, but fail to mention that there is insufficient evidence of the efficacy of both adherence monitoring tools.1 In addition, a recent article in The American Journal of Bioethics recommends against the “universal application of pain agreements” and suggests that they can harm the patient/physician relationship.2 Consent for drug testing often comes from the pain contract3—agreements that have been called “unconscionable adhesion contracts” and may be unenforceable.4

The authors also suggest that urine drug testing is noninvasive. Nothing could be further from the truth. Drug testing of people with pain may be considered a suspicionless and warrantless search of bodily fluids and in certain cases may be unconstitutional.5 There is no question that drug misuse, abuse, addiction, and overdose are devastating to individuals, families, and society. However, using unproven risk management tools that may cause greater harm than good is just bad medicine.

Mark Collen
Sacramento, Calif

References

1. Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152:712-720.

2. Payne R, Anderson E, Arnold R, et al. A rose by any other name: pain contracts/agreements. Am J Bioeth. 2010;10:5-12.

3. Collen M. Analysis of controlled substance agreements from private practice physicians. J Pain Palliat Care Pharmacother. 2009;23:357-364.

4. Collen M. Opioid contracts and random drug testing for people with chronic pain—think twice. J Law Med Ethics. 2009;37:841-845.

5. Collen M. The Fourth Amendment and random drug testing of people with chronic pain. J Pain Palliat Care Pharmacother. 2011;25:in press.

References

1. Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152:712-720.

2. Payne R, Anderson E, Arnold R, et al. A rose by any other name: pain contracts/agreements. Am J Bioeth. 2010;10:5-12.

3. Collen M. Analysis of controlled substance agreements from private practice physicians. J Pain Palliat Care Pharmacother. 2009;23:357-364.

4. Collen M. Opioid contracts and random drug testing for people with chronic pain—think twice. J Law Med Ethics. 2009;37:841-845.

5. Collen M. The Fourth Amendment and random drug testing of people with chronic pain. J Pain Palliat Care Pharmacother. 2011;25:in press.

Issue
The Journal of Family Practice - 60(3)
Issue
The Journal of Family Practice - 60(3)
Page Number
120-121
Page Number
120-121
Publications
Publications
Topics
Article Type
Display Headline
Urine drug testing: An unproven risk management tool?
Display Headline
Urine drug testing: An unproven risk management tool?
Legacy Keywords
Mark Collen; urine drug testing; consent for drug testing; pain contract; unproven risk management
Legacy Keywords
Mark Collen; urine drug testing; consent for drug testing; pain contract; unproven risk management
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Diffuse abdominal pain, vomiting

Article Type
Changed
Mon, 01/14/2019 - 11:30
Display Headline
Diffuse abdominal pain, vomiting

PRACTICE POINTERS

• Use the APACHE-II scoring system early on to help predict the severity of pancreatitis.

• Consider early enteral nutrition in patients with severe disease; taking this step has been linked to lower infection rates and shorter lengths of stay.

• Consider patient factors and the risk of severe infection when deciding whether or not to use prophylactic antibiotics in cases of severe necrotizing pancreatitis.

CASE A 57-year-old Caucasian woman sought care at our emergency department (ED) for diffuse abdominal pain and nausea. She said that the pain began after eating lunch earlier that day, and localized periumbilically, with radiation to the back. She had several episodes of nonbilious, nonbloody vomiting, but denied fever, chills, or diarrhea.

Her past medical history was notable only for an episode of gallstone pancreatitis 11 years earlier, after which she underwent a cholecystectomy. Her only medications were ibandronate sodium (Boniva) taken for osteoporosis (diagnosed 2 years earlier), a multivitamin, calcium, magnesium, and vitamin E supplements. Her family history was notable for a brother who had pancreatic cancer in his 50s. The patient reported infrequent alcohol use.

The abdominal exam was notable for diffuse tenderness to palpation, most prominent in the epigastric region. The patient exhibited voluntary guarding, without rebound, and positive bowel sounds throughout.

The patient’s laboratory studies on admission included leukocytosis of 21,300 cells/mcL and hemoglobin and hematocrit of 17.3 g/dL and 52.1%, respectively. She had an amylase of 1733 U/L and lipase of 4288 U/L. Lactate and lactic dehydrogenase were 1.83 mg/dL and 265 U/L, respectively. Liver function tests and a basic metabolic panel were within normal limits. A noncontrast computed tomography (CT) scan of the abdomen and pelvis was notable for an enlarged pancreas with peripancreatic edema and free fluid in the abdomen.

The patient underwent aggressive fluid resuscitation throughout the first 6 hours of her hospital stay. Urine output was noted to be incongruent with fluid intake, at just over 60 cc/h. Over the next 4 hours, she became progressively tachycardic, tachypneic, and somnolent, with increasing abdominal tenderness. Her serum potassium level rose to 4.9 mEq/L, while serum bicarbonate declined to 13 mEq/L and serum calcium, to 6.2 mg/dL. Arterial blood gas revealed metabolic acidosis with a pH of 7.22.

Our patient was subsequently transferred to the medical intensive care unit, where she required endotracheal intubation.

WHAT IS THE MOST LIKELY EXPLANATION FOR HER CONDITION?

Acute necrotizing pancreatitis

A repeat CT scan of the abdomen and pelvis with IV contrast taken on the second day of admission revealed extensive pancreatitis with complete disintegration of the pancreatic tissue and absence of pancreatic enhancement (FIGURE), as well as a large amount of abdominal ascites.

Pancreatitis is a common inpatient diagnosis, with approximately 200,000 hospitalizations yearly.1 Most cases are mild and self-limiting, requiring minimal intervention including parenteral fluid resuscitation, pain control, and restriction of oral intake. Most cases can be attributed to gallstones or excessive alcohol use, but approximately 25% of cases are idiopathic.1 Other causes include hypertriglyceridemia, infection, hypercalcemia, and medications such as azathioprine, 6-mercaptopurine, trimethoprim sulfa-methoxazole, and furosemide. Severe necrotizing pancreatitis represents about 20% of all cases, but carries a mortality rate of between 10% and 30%.1

Diagnosis is based on clinical features in conjunction with biochemical markers. Amylase is nonspecific, but levels 3 times the upper limit of normal are usually diagnostic of acute pancreatitis. Lipase is 85% to 100% sensitive for pancreatitis, and is more specific than amylase. Alanine aminotransferase >150 IU/L is 96% specific for gallstone pancreatitis.2 Of note: there is no evidence to support daily monitoring of these enzyme levels as predictors of clinical improvement or disease severity.

FIGURE
CT scan of abdomen taken on second day of admission

Predicting severity at time of presentation can be difficult

As was true with our patient, predicting the severity of acute pancreatitis at the time of presentation can be difficult. Scoring systems that are commonly used to evaluate disease severity include Ranson’s score, APACHE-II (Acute Physiology and Chronic Health Evaluation-II), and CT severity index, among others (TABLE). Of these, the APACHE-II score has been found to be most predictive of progression to severe disease, with accuracy of up to 75%.3

Recent studies have shown that a body mass index >30 kg/m2 is an independent risk factor for progression to severe pancreatitis.4 Other clinical predictors include poor urine output, rising hematocrit, agitation or confusion, and lack of improvement in symptoms within 48 hours.1

Though our patient came in with symptoms that were initially mild, she quickly manifested several clinical predictors for severe pancreatitis, including poor urine output and increasing confusion, as well as an APACHE-II score of 12 at 6 hours after presentation (values ≥8 indicate high risk for progression to severe disease).

 

 

TABLE
Predictors for progression to severe pancreatitis
1

Ranson score ≥3
APACHE-II score ≥8
CT severity index (CT grade + necrosis score) >6
Body mass index >30 kg/m2
Hematocrit >44% (clearly increases risk for pancreatic necrosis)
Clinical findings:
  • Thirst
  • Poor urine output
  • Progressive tachycardia or tachypnea
  • Hypoxemia
  • Agitation/confusion
Lack of improvement in symptoms within the first 48 hours
APACHE, Acute Physiology and Chronic Health Evaluation; CT, computed tomography.

Role of antibiotics? A source of debate

Infection represents the leading cause of morbidity and mortality in patients with pancreatic necrosis. Approximately 40% of patients with necrosis develop infection, with a 20% mortality rate.5 Signs of infection usually develop relatively late in the clinical course and rates increase drastically each week a patient remains hospitalized (71% of patients have signs of infection at 3 weeks).5

Interestingly, the role for antibiotics in such patients has been a source of debate in practice, as well as in the medical literature. Two recent large meta-analyses came to different conclusions regarding the use of antibiotics. A 2006 study by Heinrich et al concluded that patients with pancreatic necrosis demonstrated by contrast-enhanced CT scans should receive antibiotic prophylaxis with imipenem or meropenem for 14 days, and that prophylactic antibiotics do not increase rates of subsequent fungal infection.6 Conversely, as noted in a 2008 study published in the American Journal of Gastroenterology, “prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in patients with acute necrotizing pancreatitis.”7

Two leading professional groups have similarly contradictory recommendations on the topic, with the American Gastroenterological Association (AGA) supporting antibiotic use for patients with >30% pancreatic necrosis noted on CT and the American College of Gastroenterology (ACG) recommending against the use of prophylactic antibiotics.8

As with any clinical dilemma, it seems prudent to make the decision for or against prophylactic antibiotics based on available clinical information and the particular patient’s risk factors. Clearly, in the most high-risk patients, it would be difficult to justify withholding antibiotic therapy.

Complete bowel rest—or not?
In the past, it was thought necessary to allow for complete bowel rest and suppression of pancreatic exocrine secretion during acute pancreatitis by providing total parenteral nutrition.6,9 More recently, though, the use of early nasojejunal enteral feeding (which was initiated for our patient) has been advocated by several large meta-analyses,6 as well as by the AGA and ACG.2

The use of enteral feeding has been associated with improved outcomes, including lower infection rates (due to maintenance of the intestinal barrier and prevention of bacterial translocation), decreased length of stay, reduced rates of organ failure, and fewer deaths among patients who require surgical intervention.6

A lengthy road to recovery for our patient
After 7 days of mechanical ventilation, our patient was extubated. However, she developed significant bilateral pleural effusions as a result of fluid third spacing, and required thoracentesis.

She completed a 14-day course of imipenem, followed by an additional 10-day course due to hypotension and a suspected infected pseudocyst. Subsequent imaging studies confirmed our suspicions: She had developed a large pseudocyst (>13 cm), which remained under observation by both a gastroenterologist and general surgeon. Six weeks after admission, our patient was discharged to home with family.

But what was the cause? Although we were unable to clearly delineate an inciting cause for her pancreatitis during the admission, she was to undergo further investigation as an outpatient. There were also plans to drain the pseudocyst 6 weeks after discharge.

A learning opportunity. This patient’s case provided an excellent opportunity for our team to review the important clinical predictors for progression to severe pancreatitis, and the rapid nature of clinical decline in such patients. In hindsight, the predictors of severity in our patient were few, but included the rapid onset and clinical progression of her symptoms, as well as her elevated hematocrit on presentation and poor urine output over the first 6 hours of admission.

References

1. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med. 2006;354:2142-2150.

2. Vege SS, Whitcomb DC, Ginsburg CH. Clinical manifestations and diagnosis of acute pancreatitis. In: Basow DS. ed. UpTo-Date [online database]. Version 18.2. Waltham, Mass: UpTo-Date; 2010.

3. Vege SS, Whitcomb DC, Ginsburg CH. Predicting severity of acute pancreatitis. In: Basow DS, ed. UpToDate [online database]. Version 18.2. Waltham, Mass: UpToDate; 2010.

4. Skipworth JRA, Pereira SP. Acute pancreatitis. Curr Opin Crit Care. 2008;14:172-178.

5. Windsor JA, Schweder P. Complications of acute pancreatitis (including pseudocysts). In: Zinner MJ, Ashley SW, eds. Main-got’s Abdominal Operations. 11th ed. New York: McGraw-Hill; 2007:chap 37. Available at: http://www.accesssurgery.com/content.aspx?filename="6003JFP_HospitalRounds" aid=130125. Accessed November 30, 2010.

6. Heinrich S, Shafer M, Rousson V, et al. Evidenced-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg. 2006;243:154-168.

7. Bai Y, Gao J, Zou DW, et al. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2008;103:104-110.

8. Vege SS, Whitcomb DC, Ginsburg CH. Treatment of acute pancreatitis. In: Basow DS, ed. UpToDate [online database]. Version 18.2. Waltham, Mass: UpToDate; 2010.

9. Haney JC, Pappas TN. Necrotizing pancreatitis: diagnosis and management. Surg Clin North Am. 2007;87:1431-1446.

Article PDF
Author and Disclosure Information

Katelyn Leopold, MD
Inpatient Family Medicine, University of Cincinnati/The Christ Hospital
[email protected]

Megan Rich, MD
Inpatient Family Medicine, University of Cincinnati/The Christ Hospital

The authors reported no potential conflict of interest relevant to this article.

Issue
The Journal of Family Practice - 60(3)
Publications
Topics
Page Number
122-127
Legacy Keywords
Katelyn Leopold; diffuse abdominal pain; pancreatitis; enteral nutrition; acute necrotizing pancreatitis
Sections
Author and Disclosure Information

Katelyn Leopold, MD
Inpatient Family Medicine, University of Cincinnati/The Christ Hospital
[email protected]

Megan Rich, MD
Inpatient Family Medicine, University of Cincinnati/The Christ Hospital

The authors reported no potential conflict of interest relevant to this article.

Author and Disclosure Information

Katelyn Leopold, MD
Inpatient Family Medicine, University of Cincinnati/The Christ Hospital
[email protected]

Megan Rich, MD
Inpatient Family Medicine, University of Cincinnati/The Christ Hospital

The authors reported no potential conflict of interest relevant to this article.

Article PDF
Article PDF

PRACTICE POINTERS

• Use the APACHE-II scoring system early on to help predict the severity of pancreatitis.

• Consider early enteral nutrition in patients with severe disease; taking this step has been linked to lower infection rates and shorter lengths of stay.

• Consider patient factors and the risk of severe infection when deciding whether or not to use prophylactic antibiotics in cases of severe necrotizing pancreatitis.

CASE A 57-year-old Caucasian woman sought care at our emergency department (ED) for diffuse abdominal pain and nausea. She said that the pain began after eating lunch earlier that day, and localized periumbilically, with radiation to the back. She had several episodes of nonbilious, nonbloody vomiting, but denied fever, chills, or diarrhea.

Her past medical history was notable only for an episode of gallstone pancreatitis 11 years earlier, after which she underwent a cholecystectomy. Her only medications were ibandronate sodium (Boniva) taken for osteoporosis (diagnosed 2 years earlier), a multivitamin, calcium, magnesium, and vitamin E supplements. Her family history was notable for a brother who had pancreatic cancer in his 50s. The patient reported infrequent alcohol use.

The abdominal exam was notable for diffuse tenderness to palpation, most prominent in the epigastric region. The patient exhibited voluntary guarding, without rebound, and positive bowel sounds throughout.

The patient’s laboratory studies on admission included leukocytosis of 21,300 cells/mcL and hemoglobin and hematocrit of 17.3 g/dL and 52.1%, respectively. She had an amylase of 1733 U/L and lipase of 4288 U/L. Lactate and lactic dehydrogenase were 1.83 mg/dL and 265 U/L, respectively. Liver function tests and a basic metabolic panel were within normal limits. A noncontrast computed tomography (CT) scan of the abdomen and pelvis was notable for an enlarged pancreas with peripancreatic edema and free fluid in the abdomen.

The patient underwent aggressive fluid resuscitation throughout the first 6 hours of her hospital stay. Urine output was noted to be incongruent with fluid intake, at just over 60 cc/h. Over the next 4 hours, she became progressively tachycardic, tachypneic, and somnolent, with increasing abdominal tenderness. Her serum potassium level rose to 4.9 mEq/L, while serum bicarbonate declined to 13 mEq/L and serum calcium, to 6.2 mg/dL. Arterial blood gas revealed metabolic acidosis with a pH of 7.22.

Our patient was subsequently transferred to the medical intensive care unit, where she required endotracheal intubation.

WHAT IS THE MOST LIKELY EXPLANATION FOR HER CONDITION?

Acute necrotizing pancreatitis

A repeat CT scan of the abdomen and pelvis with IV contrast taken on the second day of admission revealed extensive pancreatitis with complete disintegration of the pancreatic tissue and absence of pancreatic enhancement (FIGURE), as well as a large amount of abdominal ascites.

Pancreatitis is a common inpatient diagnosis, with approximately 200,000 hospitalizations yearly.1 Most cases are mild and self-limiting, requiring minimal intervention including parenteral fluid resuscitation, pain control, and restriction of oral intake. Most cases can be attributed to gallstones or excessive alcohol use, but approximately 25% of cases are idiopathic.1 Other causes include hypertriglyceridemia, infection, hypercalcemia, and medications such as azathioprine, 6-mercaptopurine, trimethoprim sulfa-methoxazole, and furosemide. Severe necrotizing pancreatitis represents about 20% of all cases, but carries a mortality rate of between 10% and 30%.1

Diagnosis is based on clinical features in conjunction with biochemical markers. Amylase is nonspecific, but levels 3 times the upper limit of normal are usually diagnostic of acute pancreatitis. Lipase is 85% to 100% sensitive for pancreatitis, and is more specific than amylase. Alanine aminotransferase >150 IU/L is 96% specific for gallstone pancreatitis.2 Of note: there is no evidence to support daily monitoring of these enzyme levels as predictors of clinical improvement or disease severity.

FIGURE
CT scan of abdomen taken on second day of admission

Predicting severity at time of presentation can be difficult

As was true with our patient, predicting the severity of acute pancreatitis at the time of presentation can be difficult. Scoring systems that are commonly used to evaluate disease severity include Ranson’s score, APACHE-II (Acute Physiology and Chronic Health Evaluation-II), and CT severity index, among others (TABLE). Of these, the APACHE-II score has been found to be most predictive of progression to severe disease, with accuracy of up to 75%.3

Recent studies have shown that a body mass index >30 kg/m2 is an independent risk factor for progression to severe pancreatitis.4 Other clinical predictors include poor urine output, rising hematocrit, agitation or confusion, and lack of improvement in symptoms within 48 hours.1

Though our patient came in with symptoms that were initially mild, she quickly manifested several clinical predictors for severe pancreatitis, including poor urine output and increasing confusion, as well as an APACHE-II score of 12 at 6 hours after presentation (values ≥8 indicate high risk for progression to severe disease).

 

 

TABLE
Predictors for progression to severe pancreatitis
1

Ranson score ≥3
APACHE-II score ≥8
CT severity index (CT grade + necrosis score) >6
Body mass index >30 kg/m2
Hematocrit >44% (clearly increases risk for pancreatic necrosis)
Clinical findings:
  • Thirst
  • Poor urine output
  • Progressive tachycardia or tachypnea
  • Hypoxemia
  • Agitation/confusion
Lack of improvement in symptoms within the first 48 hours
APACHE, Acute Physiology and Chronic Health Evaluation; CT, computed tomography.

Role of antibiotics? A source of debate

Infection represents the leading cause of morbidity and mortality in patients with pancreatic necrosis. Approximately 40% of patients with necrosis develop infection, with a 20% mortality rate.5 Signs of infection usually develop relatively late in the clinical course and rates increase drastically each week a patient remains hospitalized (71% of patients have signs of infection at 3 weeks).5

Interestingly, the role for antibiotics in such patients has been a source of debate in practice, as well as in the medical literature. Two recent large meta-analyses came to different conclusions regarding the use of antibiotics. A 2006 study by Heinrich et al concluded that patients with pancreatic necrosis demonstrated by contrast-enhanced CT scans should receive antibiotic prophylaxis with imipenem or meropenem for 14 days, and that prophylactic antibiotics do not increase rates of subsequent fungal infection.6 Conversely, as noted in a 2008 study published in the American Journal of Gastroenterology, “prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in patients with acute necrotizing pancreatitis.”7

Two leading professional groups have similarly contradictory recommendations on the topic, with the American Gastroenterological Association (AGA) supporting antibiotic use for patients with >30% pancreatic necrosis noted on CT and the American College of Gastroenterology (ACG) recommending against the use of prophylactic antibiotics.8

As with any clinical dilemma, it seems prudent to make the decision for or against prophylactic antibiotics based on available clinical information and the particular patient’s risk factors. Clearly, in the most high-risk patients, it would be difficult to justify withholding antibiotic therapy.

Complete bowel rest—or not?
In the past, it was thought necessary to allow for complete bowel rest and suppression of pancreatic exocrine secretion during acute pancreatitis by providing total parenteral nutrition.6,9 More recently, though, the use of early nasojejunal enteral feeding (which was initiated for our patient) has been advocated by several large meta-analyses,6 as well as by the AGA and ACG.2

The use of enteral feeding has been associated with improved outcomes, including lower infection rates (due to maintenance of the intestinal barrier and prevention of bacterial translocation), decreased length of stay, reduced rates of organ failure, and fewer deaths among patients who require surgical intervention.6

A lengthy road to recovery for our patient
After 7 days of mechanical ventilation, our patient was extubated. However, she developed significant bilateral pleural effusions as a result of fluid third spacing, and required thoracentesis.

She completed a 14-day course of imipenem, followed by an additional 10-day course due to hypotension and a suspected infected pseudocyst. Subsequent imaging studies confirmed our suspicions: She had developed a large pseudocyst (>13 cm), which remained under observation by both a gastroenterologist and general surgeon. Six weeks after admission, our patient was discharged to home with family.

But what was the cause? Although we were unable to clearly delineate an inciting cause for her pancreatitis during the admission, she was to undergo further investigation as an outpatient. There were also plans to drain the pseudocyst 6 weeks after discharge.

A learning opportunity. This patient’s case provided an excellent opportunity for our team to review the important clinical predictors for progression to severe pancreatitis, and the rapid nature of clinical decline in such patients. In hindsight, the predictors of severity in our patient were few, but included the rapid onset and clinical progression of her symptoms, as well as her elevated hematocrit on presentation and poor urine output over the first 6 hours of admission.

PRACTICE POINTERS

• Use the APACHE-II scoring system early on to help predict the severity of pancreatitis.

• Consider early enteral nutrition in patients with severe disease; taking this step has been linked to lower infection rates and shorter lengths of stay.

• Consider patient factors and the risk of severe infection when deciding whether or not to use prophylactic antibiotics in cases of severe necrotizing pancreatitis.

CASE A 57-year-old Caucasian woman sought care at our emergency department (ED) for diffuse abdominal pain and nausea. She said that the pain began after eating lunch earlier that day, and localized periumbilically, with radiation to the back. She had several episodes of nonbilious, nonbloody vomiting, but denied fever, chills, or diarrhea.

Her past medical history was notable only for an episode of gallstone pancreatitis 11 years earlier, after which she underwent a cholecystectomy. Her only medications were ibandronate sodium (Boniva) taken for osteoporosis (diagnosed 2 years earlier), a multivitamin, calcium, magnesium, and vitamin E supplements. Her family history was notable for a brother who had pancreatic cancer in his 50s. The patient reported infrequent alcohol use.

The abdominal exam was notable for diffuse tenderness to palpation, most prominent in the epigastric region. The patient exhibited voluntary guarding, without rebound, and positive bowel sounds throughout.

The patient’s laboratory studies on admission included leukocytosis of 21,300 cells/mcL and hemoglobin and hematocrit of 17.3 g/dL and 52.1%, respectively. She had an amylase of 1733 U/L and lipase of 4288 U/L. Lactate and lactic dehydrogenase were 1.83 mg/dL and 265 U/L, respectively. Liver function tests and a basic metabolic panel were within normal limits. A noncontrast computed tomography (CT) scan of the abdomen and pelvis was notable for an enlarged pancreas with peripancreatic edema and free fluid in the abdomen.

The patient underwent aggressive fluid resuscitation throughout the first 6 hours of her hospital stay. Urine output was noted to be incongruent with fluid intake, at just over 60 cc/h. Over the next 4 hours, she became progressively tachycardic, tachypneic, and somnolent, with increasing abdominal tenderness. Her serum potassium level rose to 4.9 mEq/L, while serum bicarbonate declined to 13 mEq/L and serum calcium, to 6.2 mg/dL. Arterial blood gas revealed metabolic acidosis with a pH of 7.22.

Our patient was subsequently transferred to the medical intensive care unit, where she required endotracheal intubation.

WHAT IS THE MOST LIKELY EXPLANATION FOR HER CONDITION?

Acute necrotizing pancreatitis

A repeat CT scan of the abdomen and pelvis with IV contrast taken on the second day of admission revealed extensive pancreatitis with complete disintegration of the pancreatic tissue and absence of pancreatic enhancement (FIGURE), as well as a large amount of abdominal ascites.

Pancreatitis is a common inpatient diagnosis, with approximately 200,000 hospitalizations yearly.1 Most cases are mild and self-limiting, requiring minimal intervention including parenteral fluid resuscitation, pain control, and restriction of oral intake. Most cases can be attributed to gallstones or excessive alcohol use, but approximately 25% of cases are idiopathic.1 Other causes include hypertriglyceridemia, infection, hypercalcemia, and medications such as azathioprine, 6-mercaptopurine, trimethoprim sulfa-methoxazole, and furosemide. Severe necrotizing pancreatitis represents about 20% of all cases, but carries a mortality rate of between 10% and 30%.1

Diagnosis is based on clinical features in conjunction with biochemical markers. Amylase is nonspecific, but levels 3 times the upper limit of normal are usually diagnostic of acute pancreatitis. Lipase is 85% to 100% sensitive for pancreatitis, and is more specific than amylase. Alanine aminotransferase >150 IU/L is 96% specific for gallstone pancreatitis.2 Of note: there is no evidence to support daily monitoring of these enzyme levels as predictors of clinical improvement or disease severity.

FIGURE
CT scan of abdomen taken on second day of admission

Predicting severity at time of presentation can be difficult

As was true with our patient, predicting the severity of acute pancreatitis at the time of presentation can be difficult. Scoring systems that are commonly used to evaluate disease severity include Ranson’s score, APACHE-II (Acute Physiology and Chronic Health Evaluation-II), and CT severity index, among others (TABLE). Of these, the APACHE-II score has been found to be most predictive of progression to severe disease, with accuracy of up to 75%.3

Recent studies have shown that a body mass index >30 kg/m2 is an independent risk factor for progression to severe pancreatitis.4 Other clinical predictors include poor urine output, rising hematocrit, agitation or confusion, and lack of improvement in symptoms within 48 hours.1

Though our patient came in with symptoms that were initially mild, she quickly manifested several clinical predictors for severe pancreatitis, including poor urine output and increasing confusion, as well as an APACHE-II score of 12 at 6 hours after presentation (values ≥8 indicate high risk for progression to severe disease).

 

 

TABLE
Predictors for progression to severe pancreatitis
1

Ranson score ≥3
APACHE-II score ≥8
CT severity index (CT grade + necrosis score) >6
Body mass index >30 kg/m2
Hematocrit >44% (clearly increases risk for pancreatic necrosis)
Clinical findings:
  • Thirst
  • Poor urine output
  • Progressive tachycardia or tachypnea
  • Hypoxemia
  • Agitation/confusion
Lack of improvement in symptoms within the first 48 hours
APACHE, Acute Physiology and Chronic Health Evaluation; CT, computed tomography.

Role of antibiotics? A source of debate

Infection represents the leading cause of morbidity and mortality in patients with pancreatic necrosis. Approximately 40% of patients with necrosis develop infection, with a 20% mortality rate.5 Signs of infection usually develop relatively late in the clinical course and rates increase drastically each week a patient remains hospitalized (71% of patients have signs of infection at 3 weeks).5

Interestingly, the role for antibiotics in such patients has been a source of debate in practice, as well as in the medical literature. Two recent large meta-analyses came to different conclusions regarding the use of antibiotics. A 2006 study by Heinrich et al concluded that patients with pancreatic necrosis demonstrated by contrast-enhanced CT scans should receive antibiotic prophylaxis with imipenem or meropenem for 14 days, and that prophylactic antibiotics do not increase rates of subsequent fungal infection.6 Conversely, as noted in a 2008 study published in the American Journal of Gastroenterology, “prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in patients with acute necrotizing pancreatitis.”7

Two leading professional groups have similarly contradictory recommendations on the topic, with the American Gastroenterological Association (AGA) supporting antibiotic use for patients with >30% pancreatic necrosis noted on CT and the American College of Gastroenterology (ACG) recommending against the use of prophylactic antibiotics.8

As with any clinical dilemma, it seems prudent to make the decision for or against prophylactic antibiotics based on available clinical information and the particular patient’s risk factors. Clearly, in the most high-risk patients, it would be difficult to justify withholding antibiotic therapy.

Complete bowel rest—or not?
In the past, it was thought necessary to allow for complete bowel rest and suppression of pancreatic exocrine secretion during acute pancreatitis by providing total parenteral nutrition.6,9 More recently, though, the use of early nasojejunal enteral feeding (which was initiated for our patient) has been advocated by several large meta-analyses,6 as well as by the AGA and ACG.2

The use of enteral feeding has been associated with improved outcomes, including lower infection rates (due to maintenance of the intestinal barrier and prevention of bacterial translocation), decreased length of stay, reduced rates of organ failure, and fewer deaths among patients who require surgical intervention.6

A lengthy road to recovery for our patient
After 7 days of mechanical ventilation, our patient was extubated. However, she developed significant bilateral pleural effusions as a result of fluid third spacing, and required thoracentesis.

She completed a 14-day course of imipenem, followed by an additional 10-day course due to hypotension and a suspected infected pseudocyst. Subsequent imaging studies confirmed our suspicions: She had developed a large pseudocyst (>13 cm), which remained under observation by both a gastroenterologist and general surgeon. Six weeks after admission, our patient was discharged to home with family.

But what was the cause? Although we were unable to clearly delineate an inciting cause for her pancreatitis during the admission, she was to undergo further investigation as an outpatient. There were also plans to drain the pseudocyst 6 weeks after discharge.

A learning opportunity. This patient’s case provided an excellent opportunity for our team to review the important clinical predictors for progression to severe pancreatitis, and the rapid nature of clinical decline in such patients. In hindsight, the predictors of severity in our patient were few, but included the rapid onset and clinical progression of her symptoms, as well as her elevated hematocrit on presentation and poor urine output over the first 6 hours of admission.

References

1. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med. 2006;354:2142-2150.

2. Vege SS, Whitcomb DC, Ginsburg CH. Clinical manifestations and diagnosis of acute pancreatitis. In: Basow DS. ed. UpTo-Date [online database]. Version 18.2. Waltham, Mass: UpTo-Date; 2010.

3. Vege SS, Whitcomb DC, Ginsburg CH. Predicting severity of acute pancreatitis. In: Basow DS, ed. UpToDate [online database]. Version 18.2. Waltham, Mass: UpToDate; 2010.

4. Skipworth JRA, Pereira SP. Acute pancreatitis. Curr Opin Crit Care. 2008;14:172-178.

5. Windsor JA, Schweder P. Complications of acute pancreatitis (including pseudocysts). In: Zinner MJ, Ashley SW, eds. Main-got’s Abdominal Operations. 11th ed. New York: McGraw-Hill; 2007:chap 37. Available at: http://www.accesssurgery.com/content.aspx?filename="6003JFP_HospitalRounds" aid=130125. Accessed November 30, 2010.

6. Heinrich S, Shafer M, Rousson V, et al. Evidenced-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg. 2006;243:154-168.

7. Bai Y, Gao J, Zou DW, et al. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2008;103:104-110.

8. Vege SS, Whitcomb DC, Ginsburg CH. Treatment of acute pancreatitis. In: Basow DS, ed. UpToDate [online database]. Version 18.2. Waltham, Mass: UpToDate; 2010.

9. Haney JC, Pappas TN. Necrotizing pancreatitis: diagnosis and management. Surg Clin North Am. 2007;87:1431-1446.

References

1. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med. 2006;354:2142-2150.

2. Vege SS, Whitcomb DC, Ginsburg CH. Clinical manifestations and diagnosis of acute pancreatitis. In: Basow DS. ed. UpTo-Date [online database]. Version 18.2. Waltham, Mass: UpTo-Date; 2010.

3. Vege SS, Whitcomb DC, Ginsburg CH. Predicting severity of acute pancreatitis. In: Basow DS, ed. UpToDate [online database]. Version 18.2. Waltham, Mass: UpToDate; 2010.

4. Skipworth JRA, Pereira SP. Acute pancreatitis. Curr Opin Crit Care. 2008;14:172-178.

5. Windsor JA, Schweder P. Complications of acute pancreatitis (including pseudocysts). In: Zinner MJ, Ashley SW, eds. Main-got’s Abdominal Operations. 11th ed. New York: McGraw-Hill; 2007:chap 37. Available at: http://www.accesssurgery.com/content.aspx?filename="6003JFP_HospitalRounds" aid=130125. Accessed November 30, 2010.

6. Heinrich S, Shafer M, Rousson V, et al. Evidenced-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg. 2006;243:154-168.

7. Bai Y, Gao J, Zou DW, et al. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2008;103:104-110.

8. Vege SS, Whitcomb DC, Ginsburg CH. Treatment of acute pancreatitis. In: Basow DS, ed. UpToDate [online database]. Version 18.2. Waltham, Mass: UpToDate; 2010.

9. Haney JC, Pappas TN. Necrotizing pancreatitis: diagnosis and management. Surg Clin North Am. 2007;87:1431-1446.

Issue
The Journal of Family Practice - 60(3)
Issue
The Journal of Family Practice - 60(3)
Page Number
122-127
Page Number
122-127
Publications
Publications
Topics
Article Type
Display Headline
Diffuse abdominal pain, vomiting
Display Headline
Diffuse abdominal pain, vomiting
Legacy Keywords
Katelyn Leopold; diffuse abdominal pain; pancreatitis; enteral nutrition; acute necrotizing pancreatitis
Legacy Keywords
Katelyn Leopold; diffuse abdominal pain; pancreatitis; enteral nutrition; acute necrotizing pancreatitis
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media